<SEC-DOCUMENT>0001193125-23-296814.txt : 20231215
<SEC-HEADER>0001193125-23-296814.hdr.sgml : 20231215
<ACCEPTANCE-DATETIME>20231215172930
ACCESSION NUMBER:		0001193125-23-296814
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231214
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231215
DATE AS OF CHANGE:		20231215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Syndax Pharmaceuticals Inc
		CENTRAL INDEX KEY:			0001395937
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				320162505
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37708
		FILM NUMBER:		231491492

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-419-1400

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d50500d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sndx="http://www.syndax.com/20231214" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-12-14_to_2023-12-14">Syndax Pharmaceuticals Inc</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-14_to_2023-12-14">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-14_to_2023-12-14">0001395937</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="sndx-20231214.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-14_to_2023-12-14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-14</xbrli:startDate> <xbrli:endDate>2023-12-14</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-14_to_2023-12-14">8-K</ix:nonNumeric></span></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported):</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt:datemonthdayyearen">December&#160;14, 2023</ix:nonNumeric></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">SYNDAX PHARMACEUTICALS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-14_to_2023-12-14">001-37708</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-14_to_2023-12-14">32-0162505</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(state or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:33%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-14_to_2023-12-14">Building D</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-12-14_to_2023-12-14">Floor 3</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-12-14_to_2023-12-14">35 Gatehouse Drive</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-14_to_2023-12-14">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-14_to_2023-12-14">02451</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-14_to_2023-12-14">(781)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-14_to_2023-12-14">419-1400</ix:nonNumeric></span></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered or to be registered pursuant to Section&#160;12(b) of the Act.</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-14_to_2023-12-14">Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-14_to_2023-12-14">SNDX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:exchnameen">The Nasdaq Stock Market, LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-14_to_2023-12-14" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:7pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2023, Syndax Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) entered into an underwriting agreement (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriting Agreement</span></span>&#8221;) with Goldman Sachs&#160;&amp; Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriters</span></span>&#8221;), relating to the issuance and sale of 10,810,810 shares of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221;), at a price to the public of $18.50 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offering</span></span>&#8221;). In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,621,621 shares of Common Stock. The gross proceeds to the Company from the Offering are expected to be approximately $200.0&#160;million (or approximately $230.0&#160;million if the Underwriters exercise their option to purchase additional shares in full), before deducting underwriting discounts and commissions and offering expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Offering is being made pursuant to the Company&#8217;s shelf registration statement <span style="white-space:nowrap">on&#160;Form&#160;S-3</span> (File <span style="white-space:nowrap">No.&#160;333-254661),</span> which became effective upon filing with the Securities and Exchange Commission on March&#160;24, 2021, a base prospectus dated March&#160;24, 2021 and the related prospectus supplement dated December&#160;14, 2023. The Offering is expected to close on or about December&#160;19, 2023, subject to satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters, including for liabilities under the&#160;Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties, covenants and agreements contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. All of the Company&#8217;s directors and executive officers and certain stockholders have agreed, subject to certain exceptions, not to sell or transfer any shares of Common Stock for 60 days, and the Company has agreed not to sell or transfer any shares of the Common Stock for 60 days, in each case, after December&#160;14, 2023, without first obtaining the written consent of Goldman Sachs&#160;&amp; Co. LLC and J.P. Morgan Securities LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is each qualified in its entirety by reference to the Underwriting Agreement, which is attached as Exhibit 1.1 hereto, respectively, and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d50500dex11.htm">Underwriting Agreement, dated December&#160;14, 2023, by and between the Company and Goldman Sachs&#160;&amp; Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d50500dex51.htm">Opinion of Cooley LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d50500dex51.htm">Consent of Cooley LLP (included in Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">SYNDAX PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">/</span>s<span style="font-weight:bold">/ </span>Luke J. Albrecht</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Luke J. Albrecht</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">General Counsel and Secretary</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&#160;15, 2023 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d50500dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10,810,810 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SYNDAX PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK (PAR VALUE $0.0001 PER SHARE) </B></P>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;14, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;14, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Syndax Pharmaceuticals,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to the several Underwriters named in <U>Schedule</U><U></U><U>&nbsp;I</U> hereto (the &#147;<B>Underwriters</B>&#148;) 10,810,810 shares of its common stock,
par value $0.0001 per share (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue and sell to the several Underwriters not more than an additional 1,621,621 shares of its common stock, par value $0.0001 per share (the
&#147;<B>Additional Shares</B>&#148;), if and to the extent that you, as representatives of the several Underwriters (the &#147;<B>Representatives</B>&#148;), shall have determined to exercise, on behalf of the Underwriters, the right to purchase
such shares of common stock granted to the Underwriters in <U>Section</U><U></U><U>&nbsp;2</U> hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<B>Shares</B>.&#148; The shares of common stock,
par value $0.0001 per share of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148; To the extent there are no additional Underwriters listed in
Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-254661),</FONT> which became effective upon filing on March&nbsp;24, 2021 and includes a prospectus relating to the securities set forth on such Form <FONT
STYLE="white-space:nowrap">S-3ASR,</FONT> including the Shares and other securities to be issued from time to time by the Company. The registration statement as amended at the time it automatically became effective upon filing, including the
information (if any) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed to be part of the registration statement at the time of effectiveness pursuant to Rule 430B under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is
hereinafter referred to as the &#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to confirm sales of Shares (or in the form first made available to the Underwriters by the Company to meet requests of purchasers
pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>&#148; and the term &#147;<B>preliminary prospectus</B>&#148; means any preliminary form of the Prospectus. If the Company has filed an
abbreviated registration statement to register additional shares of Common Stock pursuant to Rule&nbsp;462(b) under the Securities Act (the &#147;<B>Rule</B><B></B><B>&nbsp;462</B><B> Registration Statement</B>&#148;), then any reference herein to
the term &#147;<B>Registration Statement</B>&#148; shall be deemed to include such Rule&nbsp;462 Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of
this underwriting agreement (the &#147;<B>Agreement</B>&#148;), &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus
latest in use prior to the Applicable Time together with the documents and pricing information set forth in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road
show&#148; as defined in Rule 433(h)(5) under the Securities Act that has been made available without restriction to any person. As used herein, the terms &#147;<B>Registration Statement</B>,&#148; &#147;<B>preliminary prospectus</B>,&#148;
&#147;<B>Time of Sale Prospectus</B>&#148; and &#147;<B>Prospectus</B>&#148; shall include the documents, if any, incorporated by reference therein as of the date hereof. The terms &#147;<B>supplement</B>,&#148; &#147;<B>amendment</B>&#148; and
&#147;<B>amend</B>&#148; as used herein with respect to the Registration Statement, the Prospectus, the Time of Sale Prospectus or any preliminary prospectus shall include all documents subsequently filed by the Company with the Commission pursuant
to the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), that are deemed to be incorporated by reference therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as used in this Agreement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Time</B>&#148; means 8:30 p.m. (New York time) on the date of this Agreement or such other time as agreed to by the
Company and the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>General Use Free Writing Prospectus</B>&#148; means any Issuer Free Writing Prospectus (other
than a broadly available road show or the pricing information identified on <U>Schedule II</U> hereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuer Free Writing
Prospectus</B>&#148; means any &#147;issuer free writing prospectus&#148;, as defined in Rule 433 under the Securities Act, including without limitation any &#147;free writing prospectus&#148; relating to the Shares that is (i)&nbsp;required to be
filed with the Commission by the Company, (ii)&nbsp;a &#147;road show that is a written communication&#148; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission or (iii)&nbsp;excepted from filing with the
Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be
filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Limited Use Free Writing Prospectus</B>&#148; means any Issuer Free Writing
Prospectus that is not a General Use Free Writing Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations and Warranties</I>. The
Company represents and warrants to and agrees with each of the Underwriters that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement
became automatically effective upon filing; no stop order suspending the effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;(i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by
reference in the Time of Sale Prospectus or the Prospectus complied or will comply when so filed in all material respects with the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii)&nbsp;the Registration
Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain, as of the date of such amendment or supplement, any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading, (iii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or supplemented, if applicable, will comply, as of the date of such amendment or
supplement, in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iv)&nbsp;the Time of Sale Prospectus does not, and at the time of each sale of the Shares in connection with the
offering when the Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in <U>Section</U><U></U><U>&nbsp;4</U>), the Time of Sale Prospectus, as then amended or supplemented by the Company, if applicable, will
not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, (v)&nbsp;each broadly available road show,
if any, when considered together with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading and (vi)&nbsp;the Prospectus does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Registration Statement, the Time of Sale
Prospectus or the Prospectus based upon information relating to any Underwriter furnished to the Company by or on behalf of any Underwriter through the Representatives, specifically for use therein, it being understood and agreed that the only such
information is that described in <U>Section</U><U></U><U>&nbsp;14</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Any free writing prospectus that
the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act and the applicable rules and regulations of the Commission
thereunder. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or that was prepared by or behalf of or used or referred to by the Company complies or, if filed after the effective date of this Agreement, will comply, when filed, in all material respects with
the requirements of the Securities Act and the applicable rules and regulations of the Commission thereunder. Except for the free writing prospectuses, if any, identified in <U>Schedule</U><U></U><U>&nbsp;II</U> hereto, and electronic road shows, if
any, each furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior consent, prepare, use or refer to, any free writing prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the
State of Delaware, with requisite power and authority to own or lease its properties and conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The Company does not own or control, directly
or indirectly, any corporation, association or other entity other than the subsidiaries listed in <U>Schedule III</U> hereto. Each subsidiary has been duly organized and is validly existing as a corporation, limited liability company or similar
entity in good standing under the laws of the jurisdiction of its organization with requisite power and authority to own or lease its properties and conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus. The Company does not have any significant subsidiaries (as defined in Rule 405 under the Securities Act). The Company and its subsidiaries are duly qualified to transact business in all jurisdictions in which the conduct of their
business requires such qualification except where the failure to be so qualified would not (i)&nbsp;have, individually or in the aggregate, a material adverse effect on the earnings, business, properties, assets, liabilities, operations, condition
(financial or otherwise) or prospects of the Company and its subsidiaries taken as a whole or (ii)&nbsp;prevent the consummation of the transactions contemplated hereby (the occurrence of any such effect or any such prevention described in the
foregoing clauses (i)&nbsp;and (ii) being referred to as a &#147;<B>Material Adverse Effect</B>&#148;). The outstanding shares of capital stock of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned by the Company free and clear of all liens, encumbrances and equities and claims as would not, in the aggregate, reasonably be expected to have a Material Adverse Effect; and
no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligations into shares of capital stock or ownership interests in such subsidiaries are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The outstanding shares of Common Stock of the Company have been duly authorized and validly issued and are fully
paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> the Shares to be issued and sold by the Company have been duly authorized and when issued and paid for as contemplated herein will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable;</FONT> and no preemptive or similar rights of stockholders exist with respect to any of the Shares or the issue and sale thereof. Neither the filing of the Registration Statement nor the offering or sale of
the Shares as contemplated by this Agreement gives rise to any rights, other than those which have been waived or satisfied, for or relating to the registration of any shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;All of the Shares conform to the description thereof contained in
the Registration Statement, the Time of Sale Prospectus and the Prospectus. The form of certificate for the Shares conforms to the corporate law of the jurisdiction of the Company&#146;s incorporation and to any requirements of the Company&#146;s
organizational documents. Subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus, except as otherwise specifically stated therein or in this Agreement, the
Company has not: (i)&nbsp;issued any securities other than for subsequent issuances, if any, or upon the exercise of outstanding options or warrants, in each case as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus; (ii)&nbsp;incurred any liability or obligation, direct or contingent, for borrowed money; or (iii)&nbsp;declared or paid any dividend or made any other distribution on or in respect to its capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration
Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Company has not, directly or indirectly, distributed and will not distribute any offering material in
connection with the offering and sale of the Shares other than any Preliminary Prospectus, the Prospectus and other materials, if any, permitted under the Securities Act and consistent with <U>Section</U><U></U><U>&nbsp;5(b)</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;(i) At the time of filing the Registration Statement and (ii)&nbsp;as of the date hereof (with such date being used
as the determination date for purposes of this clause (ii)), the Company was not and is not an &#147;ineligible issuer&#148; (as defined in Rule 405 under the Securities Act, without taking into account any determination by the Commission pursuant
to Rule 405 under the Securities Act that it is not necessary that the Company be considered an ineligible issuer), including, without limitation, for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares
as contemplated by the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of the Company and its
subsidiaries, together with related notes and schedules as set forth or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, comply in all material respects with the applicable requirements of the
Securities Act and present fairly, in all material respects, the financial position of the Company and its subsidiaries at the indicated dates and the results of operations, changes in stockholders&#146; equity and cash flows of the Company and its
subsidiaries for the indicated periods. Such financial statements and related schedules have been prepared in accordance with United States generally accepted principles of accounting (&#147;<B>GAAP</B>&#148;), consistently applied throughout the
periods involved, except as disclosed in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain
certain footnotes as permitted by the applicable rules of the Commission, and all adjustments necessary for a fair presentation of results for such periods have been made. The pro forma financial information, if any, included in the Registration
Statement, the Time of Sale Prospectus and the Prospectus present fairly the information shown therein, have been prepared in accordance with the Commission&#146;s rules and guidelines with respect to pro forma financial statements, have been
properly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compiled on the pro forma bases described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the
transactions or circumstances referred to therein. The Company and its subsidiaries do not have any material liabilities or obligations, direct or contingent (including any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet obligations or any
&#147;variable interest entities&#148; within the meaning of Financial Accounting Standards Board Interpretation No.&nbsp;46), not disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus. There are no financial
statements (historical or pro forma) that are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus that are not included as
required.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;Deloitte&nbsp;&amp; Touche LLP, who have certified certain of the financial statements filed with the Commission as
part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities Act and the applicable
rules and regulations and the Public Company Accounting Oversight Board (United States) (the &#147;<B>PCAOB</B>&#148;) as required by the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;There is and has been no failure on the part of the Company or any of the Company&#146;s directors or officers, in
their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906
related to certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;There is no legal, governmental, administrative or regulatory investigation,
action, suit, claim or proceeding pending or, to the knowledge of the Company, threatened against the Company or its subsidiaries, or to which any property of the Company or any of its subsidiaries is, or to the knowledge of the Company, would
reasonably be expected to be, subject, before any court or regulatory or administrative agency or otherwise which if determined adversely to the Company or any such subsidiary would, individually or in the aggregate, have a Material Adverse Effect.
There are no current or pending legal, governmental, administrative or regulatory investigations, actions, suits, claims or proceedings that are required under the Securities Act to be described in the Registration Statement, the Time of Sale
Prospectus or the Prospectus that are not so described in the Registration Statement, the Time of Sale Prospectus or the Prospectus. There are no contracts or other documents that are required under the Securities Act to be filed as exhibits to the
Registration Statement or described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Time of Sale Prospectus
or the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries have good and marketable title to all of the properties
and assets reflected in the consolidated financial statements hereinabove described or described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subject to no lien, mortgage, pledge, charge or encumbrance of any kind
except those reflected in such financial statements or described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or which (i)&nbsp;do not materially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;would, individually or in the aggregate, have a Material Adverse Effect. The
Company and its subsidiaries occupy their leased properties under valid and binding leases conforming in all material respects to the description thereof set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries have filed all U.S. federal, state, local and foreign tax returns which have been
required to be filed and have paid all taxes indicated by such returns and all assessments received by them or any of them to the extent that such taxes have become due. All tax liabilities have been adequately provided for in the financial
statements of the Company, and the Company does not know of any actual or proposed additional material tax assessments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the most recent financial statements included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;there has not been any material adverse change or any development involving a prospective material adverse change in or affecting the earnings, business, management, properties,
assets, rights, operations, condition (financial or otherwise), or prospects of the Company and its subsidiaries taken as a whole, whether or not occurring in the ordinary course of business, (ii)&nbsp;there has not been any material transaction
entered into or any material transaction that is probable of being entered into by the Company or its subsidiaries, other than transactions in the ordinary course of business, as each may be amended or supplemented, and (iii)&nbsp;neither the
Company nor its subsidiaries have sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as has been disclosed in the Registration Statement, the Time of Sale
Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries is or with the giving of notice
or lapse of time or both, will be, (i)&nbsp;in violation of its certificate or articles of incorporation, charter, <FONT STYLE="white-space:nowrap">by-laws,</FONT> certificate of formation, limited liability company agreement, partnership agreement
or other organizational documents, as applicable, (ii)&nbsp;in violation of or in default under any agreement, lease, contract, indenture or other instrument or obligation to which it is a party or by which it, or any of its properties, is bound or
(iii)&nbsp;in violation of any law, order, rule or regulation judgment, order, writ or decree applicable to the Company or any of its subsidiaries of any court or of any government, regulatory body or administrative agency or other governmental body
having jurisdiction over the Company or such subsidiary, or any of their properties or assets, except in the case of clauses (ii)&nbsp;and (iii), for such violations or defaults as would not, individually or in the aggregate, have a Material Adverse
Effect. The execution and delivery of this Agreement and the consummation of the transactions herein contemplated and the fulfillment of the terms hereof do not and will not conflict with or result in a breach of any of the terms or provisions of,
or constitute a default under, (A)&nbsp;any indenture, mortgage, deed of trust or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsidiaries or any of their respective properties is bound, or of (B)&nbsp;the certificate of incorporation or formation, articles of incorporation or association, charter, <FONT
STYLE="white-space:nowrap">by-laws</FONT> or other organizational documents, as applicable, of the Company or (C)&nbsp;any law, order, rule or regulation judgment, order, writ or decree applicable to the Company or any of its subsidiaries of any
court or of any government, regulatory body or administrative agency or other governmental body having jurisdiction over the Company or any such subsidiary, or any of their properties or assets, except, with respect to (A)&nbsp;and (C), for such
violations as would not, individually or in the aggregate, result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;The execution
and delivery of, and the performance by the Company of its obligations under, this Agreement has been duly and validly authorized by all necessary corporate, limited liability company or similar applicable action on the part of the Company, and this
Agreement has been duly executed and delivered by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;Each approval, consent, order, authorization,
designation, declaration or filing by or with any regulatory, administrative or other governmental body necessary in connection with the execution and delivery by the Company of this Agreement and the consummation of the transactions herein
contemplated has been obtained or made and is in full force and effect (except such additional steps as may be required by the Commission, the Financial Industry Regulatory Authority, Inc. (&#147;<B>FINRA</B>&#148;) or such additional steps as may
be necessary to qualify the Shares for public offering by the Underwriters under state securities or Blue Sky laws). All of the information provided to the Underwriters or counsel to the Underwriters by the Company, its counsel, its officers and
directors and the holders of any securities or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct in all material respects, and is compliant with FINRA&#146;s rules. Any
letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;Except as would not, individually or in the aggregate, have a Material Adverse Effect, the Company and its
subsidiaries (i)&nbsp;hold all licenses, registrations, certificates and permits from governmental authorities (collectively, &#147;<B>Governmental Licenses</B>&#148;), which are necessary to the conduct of their business, (ii)&nbsp;are in
compliance with the terms and conditions of all Governmental Licenses, and all Governmental Licenses are valid and in full force and effect, and (iii)&nbsp;have not received any written or other notice of proceedings relating to the revocation or
modification of any Governmental License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise disclosed in the Registration Statement, the
Time of Sale Prospectus, and the Prospectus, the Company and its subsidiaries own or have obtained licenses for all patents, patent applications, inventions, trademarks, trade names, service marks, logos, trade dress, designs, data, database rights,
Internet domain names, rights of privacy, rights of publicity, copyrights, works of authorship, license rights, trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information (including unpatented and unpatentable
proprietary or confidential information, inventions, systems or procedures) and other industrial property and intellectual property rights described in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Statement, the Time of Sale Prospectus, and the Prospectus as being owned or licensed by them, as well as related rights, such as moral rights and the right to sue for all past, present and
future infringements or misappropriations of any of the foregoing, and registrations and applications for registration of any of the foregoing (collectively, &#147;<B>Intellectual Property</B>&#148;) necessary in all material respects for the
conduct of their business as presently conducted and as presently proposed to be conducted in the future as disclosed in the Registration Statement, the Time of Sale Prospectus, and the Prospectus, and such Intellectual Property has not been
adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. Neither the Company nor any of its subsidiaries has materially infringed, misappropriated, otherwise violated, or is currently materially infringing,
misappropriating, or otherwise violating, and none of the Company or any of its subsidiaries has received any communication or notice of infringement of, misappropriation of, conflict with or violation of, any Intellectual Property of any other
person or entity. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for (x)&nbsp;customary reversionary rights of third-party licensors with respect to Intellectual Property
that are disclosed in the Registration Statement, the Time of Sale Prospectus, and the Prospectus as licensed to the Company or its subsidiaries and (y)&nbsp;third parties who have been explicitly granted licenses by the Company; and (ii)&nbsp;there
is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any
Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the
Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company infringes, misappropriates, or otherwise violates, or would, upon the commercialization of any
product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe, misappropriate, or violate, any patent, trademark, trade name, service name, copyright, trade secret or other
proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied in all material respects with the terms of each
agreement pursuant to which Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect. The Company and its subsidiaries have taken all reasonable steps necessary to secure their interests in the
Intellectual Property from their employees and contractors and to protect the confidentiality of all of their confidential information and trade secrets. The product candidates described in the Registration Statement, the Time of Sale Prospectus and
the Prospectus as under development by the Company fall within the scope of the claims of one or more patents or patent applications owned by, or exclusively licensed to, the Company. To the Company&#146;s knowledge, there is no patent or published
patent application in the U.S. or other jurisdiction which contains claims that dominate or may dominate the Intellectual Property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or that interferes with the
issued or pending claims of any such Intellectual Property (for the avoidance of doubt, the Company makes no such representation as to the intellectual property covering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">PD1/PD-L1</FONT> inhibitors described therein as owned or controlled by third parties). There is no prior art of which the Company is aware that would render any
patent held by the Company invalid, except as would not, individually or in the aggregate, have a Material Adverse Effect, and all prior art of which the Company is aware that may be material to the validity of a U.S. patent or to the patentability
of a U.S. patent application has been disclosed to the U.S. Patent and Trademark Office, and all such prior art has been disclosed to the patent office of other jurisdictions where required. To the Company&#146;s knowledge, there are no material
defects in any of the patents or patent applications included in the Intellectual Property. To the Company&#146;s knowledge, the duties of candor and good faith required by the United States Patent and Trademark Office during the prosecution of the
United States patents and patent applications included in the Intellectual Property have been complied with, and all such requirements in foreign offices having similar requirements applicable to the Company or its subsidiaries have been complied
with. To the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation
relates to such employee&#146;s employment with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries&#146;
information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as
required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its
subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of
all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#147;<B>Personal Data</B>&#148;)) used in connection with their businesses, and there have been no breaches, violations, outages or
unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company
and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. The Company and its subsidiaries have taken
all necessary actions to prepare to comply with the European Union General Data Protection Regulation (and all other applicable laws and regulations with respect to Personal Data that have been announced as of the date hereof as becoming effective
within 12 months after the date hereof, and for which any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with same would be reasonably likely to create a material liability) as soon they take effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;None of the Intellectual Property or technology (including
information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiaries in violation of any contractual obligation binding on the Company or its
subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;None of the Company or its subsidiaries nor, to the Company&#146;s knowledge, any of their affiliates, has taken or
may take, directly or indirectly, any action designed to cause or result in, or which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of the shares of Common Stock to facilitate the
sale or resale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries is or, after giving effect to
the offering and sale of the Shares contemplated hereunder and the application of the net proceeds from such sale as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, will be required to register as an
&#147;investment company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively,
the &#147;<B>1940 Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a system of &#147;internal control over financial
reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific
authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Other than as described in the Registration Statement, Time
of Sale Prospectus and the Prospectus, there are no material weaknesses in the Company&#146;s internal control over financial reporting, and there has been no change in internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, the Company&#146;s internal control over financial reporting since the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The
Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;The Company has established and maintains &#147;disclosure
controls and procedures&#148; (as defined in Rules <FONT STYLE="white-space:nowrap">13a-14(c)</FONT> and <FONT STYLE="white-space:nowrap">15d-14(c)</FONT> under the Exchange Act); the Company&#146;s &#147;disclosure controls and procedures&#148; are
reasonably designed to ensure that all information (both financial and <FONT STYLE="white-space:nowrap">non-financial)</FONT> required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the rules and regulations under the Exchange Act, and that all such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely
decisions regarding required disclosure and to make the certifications of the Chief Executive Officer and Chief Financial Officer of the Company required under the Exchange Act with respect to such reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;The statistical, industry-related and market-related data included or incorporated by reference in the
Registration Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are
derived. To the extent required, the Company has obtained the written consent to the use of such data from such sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with all
applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act
of 2001 (USA PATRIOT Act), the Currency and Foreign Transactions Reporting Act of 1970, as amended, and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Anti-Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor its subsidiaries or any of their directors or officers nor, to the Company&#146;s
knowledge, any employee, agent, affiliate or representative of the Company or its subsidiaries, is an individual or entity (&#147;<B>Person</B>&#148;) that is, or is owned or controlled by a Person that is: (A)&nbsp;the subject of any sanctions
administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury or other relevant sanctions authority (collectively,
&#147;<B>Sanctions</B>&#148;), nor (B)&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the Crimea Region and the <FONT STYLE="white-space:nowrap">non-government</FONT>
controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba,
Iran, North Korea and Syria). The Company will not, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: to fund or
facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or in any other manner that will result in a violation of Sanctions by any
Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise). For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will
not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor its subsidiaries or any of their directors or officers nor, to the Company&#146;s
knowledge, any employee, agent, affiliate or representative of the Company or its subsidiaries, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or giving of money,
property, gifts or anything else of value, directly or indirectly, to any &#147;government official&#148; (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any
person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) to influence official action or secure an improper advantage; and the Company and its
subsidiaries and affiliates have conducted their businesses in compliance with the OECD Convention on Bribery of Foreign Public Officials in International Business Transactions, the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder, the U.K. Bribery Act 2010 or any similar law or regulation to which the Company, its subsidiaries, any director, officer, agent, employee, affiliate or other person associated with or acting on behalf of the Company or
its subsidiaries is subject, and they have instituted and maintain and will continue to maintain policies and procedures designed to promote and achieve compliance with such laws and with the representation and warranty contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;The Company carries, or is covered by, insurance, from insurers of recognized financial responsibility, in such
amounts and covering such risks as is adequate for the conduct of its businesses and the value of its properties and as is prudent and customary for a company engaged in a similar business; the Company has not been refused any coverage under
insurance policies sought or applied for; and the Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;Each &#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3) of the Employee Retirement Income
Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;<B>ERISA</B>&#148;)) for which the Company or any member of its &#147;Controlled Group&#148; (defined as any organization that is a member of
a controlled group of corporations within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;)), including its subsidiaries, would have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liability (each a &#147;<B>Plan</B>&#148;) is in compliance in all material respects with all presently applicable statutes, rules and regulations, including ERISA and the Code; (ii)&nbsp;with
respect to each Plan subject to Title IV of ERISA (a)&nbsp;no &#147;reportable event&#148; (as defined in Section&nbsp;4043 of ERISA) has occurred for which the Company or any member of its Controlled Group would have any liability; and
(b)&nbsp;neither the Company nor any member of its Controlled Group has incurred or expects to incur liability under Title IV of ERISA (other than for contributions to the Plan or premiums payable to the Pension Benefit Guaranty Corporation, in each
case in the ordinary course and without default); (iii) no Plan which is subject to Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA has failed to satisfy the minimum funding standard within the meaning of such sections of the Code or
ERISA; and (iv)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;There are no affiliations or associations between any member of FINRA and any of the Company&#146;s or its
subsidiaries&#146; officers, directors or 5% or greater securityholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Except in each case as otherwise
disclosed or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;the Company and its subsidiaries have complied and are in compliance, in all material respects, with all applicable
federal, state, local, foreign and international laws (including the common law), statutes, rules, regulations, orders, judgments, decrees or other legally binding requirements of any court, administrative agency or other governmental authority
relating to pollution or to the protection of the environment, natural resources or human health or safety, or to the manufacture, use, generation, treatment, storage, disposal, release or threatened release of hazardous or toxic substances,
pollutants, contaminants or wastes, or the arrangement for such activities (&#147;<B>Environmental Laws</B>&#148;); (ii) the Company and its subsidiaries have obtained and are in compliance, in all material respects, with all permits, licenses,
authorizations or other approvals required of them under Environmental Laws to conduct their respective businesses and are not subject to any action to revoke, terminate, cancel, limit, amend or appeal any such permits, licenses, authorizations or
approvals; (iii)&nbsp;neither the Company nor its subsidiaries is a party to any judicial or administrative proceeding (including a notice of violation) under any Environmental Laws (a)&nbsp;to which a governmental authority is also a party and
which involves potential monetary sanctions, unless it could reasonably be expected that such proceeding will result in monetary sanctions of less than $100,000, or (b)&nbsp;which is otherwise material; and no such proceeding has been threatened or
is known to be contemplated; (iv)&nbsp;neither the Company nor its subsidiaries has received notice or is otherwise aware of any pending or threatened material claim or potential liability under Environmental Laws in respect of its past or present
business, operations (including the disposal of hazardous substances at any <FONT STYLE="white-space:nowrap">off-site</FONT> location), facilities or real property (whether owned, leased or operated) or on account of any predecessor or any person
whose liability under any Environmental Laws it has agreed to assume; and neither the Company nor its subsidiaries is aware of any facts or conditions that could reasonably be expected to give rise to any such claim or liability; and
(v)&nbsp;neither the Company nor its subsidiaries is aware of any matters regarding compliance with existing or reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
anticipated Environmental Laws, or with any liabilities or other obligations under Environmental Laws (including asset retirement obligations), that could reasonably be expected to have a
material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;[Reserved] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;There are no relationships, direct or indirect, or related-party transactions involving the Company or its
subsidiaries or any other person required to be described in the Registration Statement and the Prospectus which have not been described in such documents and the Time of Sale Prospectus as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the
Company, from making any other distribution on such subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s property or assets to the
Company or any other subsidiary of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;No labor disturbance by or dispute with employees of the
Company or its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor its subsidiaries is a party to any contract, agreement or understanding with any person
(other than this Agreement) that would give rise to a valid claim against the Company or its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;The preclinical tests and clinical trials, and other studies (collectively, &#147;<B>studies</B>&#148;) that are
described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures
and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived
from such studies, and the Company has no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or
the Prospectus; the Company or, to the Company&#146;s knowledge, the clinical trial sponsor of the trials or studies, has made all such filings and obtained all such approvals or authorizations as may be required by the Food and Drug Administration
of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board or independent ethics committee (collectively, the
&#147;<B>Regulatory</B><B><I> </I></B><B>Agencies</B>&#148;), except where the failure to make such filing or obtain such approval would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect; except as
described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company and, to the Company&#146;s knowledge, the clinical trial sponsor of such trials, has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to
in the Registration Statement, the Time of Sale Prospectus, nor is the Company aware of any reasonable grounds for such notice or correspondence; and the Company has operated and currently is in compliance in all material respects with all
applicable rules and regulations of the Regulatory Agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries are, and at all
times have been, in compliance with all state, federal and foreign Health Care Laws applicable to the Company and its subsidiaries&#146; respective businesses, and the Company and its subsidiaries are in compliance with Health Care Laws, except
where the failure to do so would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have not engaged in activities which to its knowledge are cause for false claims liability, civil penalties, or mandatory
or permissive exclusion from Medicare, Medicaid, or any other state health care program or federal health care program. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means the: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. &#167; 301 et seq.) and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the federal criminal false claims law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(a)),</FONT> the
federal civil monetary penalties law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7a),</FONT> the Stark Law (42 U.S.C. &#167;1395nn), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health
Insurance Portability and Accountability Act of 1996 (&#147;<B>HIPAA</B>&#148;) (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C. <FONT STYLE="white-space:nowrap">&#167;1320a-7),</FONT> the statutes and regulations government
healthcare programs, including the European Union General Data Protection Regulation (EU 2016 679), Medicare, Title XVIII of the Social Security Act, and Medicaid, Title XIX of the Social Security Act, and the regulations promulgated pursuant to
such statutes; (iii)&nbsp;the U.S. federal Prescription Drug Marketing Act of 1987, as amended, and the regulations promulgated thereunder; (iv)&nbsp;the U.S. Controlled Substances Act; (v)&nbsp;the Clinical Laboratory Improvement Act; and
(vi)&nbsp;the Standards for Privacy of Individually Identifiable Health Information, the Security Standards, and the Standards for Electronic Transactions and Code Sets promulgated under HIPAA, the Health Information Technology for Economic and
Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), and the regulations promulgated thereunder and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof or other law or regulation the purpose of which is to
protect the privacy of individuals or prescribers. Neither the Company nor its subsidiaries have received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other material action from any court
or arbitrator or governmental or regulatory authority or third party alleging that any product, operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
were corrected or supplemented by a subsequent submission). Neither the Company nor its subsidiaries are a party to any corporate integrity agreements, monitoring agreements, consent decrees,
plans of correction, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, its subsidiaries nor any of their respective employees, officers or directors has been
excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that
would reasonably be expected to result in debarment, suspension, or exclusion. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by the Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were timely, complete, accurate and not misleading on the
date filed in all material respects (or were corrected or supplemented by a subsequent submission). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;The Company (i)&nbsp;has not engaged in any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, and (ii)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any
oral or written communication with potential investors undertaken in reliance on Section&nbsp;5(d) or Rule 163B of the Securities Act. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several Underwriters, and each
Underwriter, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to purchase from the Company the respective numbers of Firm Shares set forth in
<U>Schedule</U><U></U><U>&nbsp;I</U> hereto opposite its name at $17.39 a share (the &#147;<B>Purchase Price</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of
the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and the Underwriters shall have the right to purchase, severally and not
jointly, up to 1,621,621 Additional Shares at the Purchase Price, provided, however, that the amount paid by the Underwriters for any Additional Shares shall be reduced by an amount per share equal to any dividends declared by the Company and
payable on the Firm Shares but not payable on such Additional Shares. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by giving written notice to the Company not later than 30 days
after the date of this Agreement. Any exercise notice shall specify the number of Additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares to be purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase date must be at least one business day after the written notice is given and may
not be earlier than the closing date for the Firm Shares nor later than 10 business days after the date of such notice. On each day, if any, that Additional Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter
agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion to the total number of Additional Shares to be purchased
on such Option Closing Date as the number of Firm Shares set forth in <U>Schedule</U><U></U><U>&nbsp;I</U> hereto opposite the name of such Underwriter bears to the total number of Firm Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Terms of Public Offering</I>. The Company is advised by you that the Underwriters propose to make a public
offering of their respective portions of the Shares as soon as after the Registration Statement and this Agreement have become effective as in your judgment is advisable. The Company is further advised by you that the Shares are to be offered to the
public initially at $18.50 a share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<I>Payment and Delivery. </I>Payment for the Firm Shares shall be made to
the Company in Federal or other funds immediately available in New York City against delivery of such Firm Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on December&nbsp;19, 2023, or at such other
time on the same date, as shall be designated in writing by you. The time and date of such payment are hereinafter referred to as the &#147;<B>Closing Date</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for any Additional Shares shall be made to the Company in Federal or other funds immediately available in New York City against
delivery of such Additional Shares for the respective accounts of the several Underwriters at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in <U>Section</U><U></U><U>&nbsp;2 </U>or at such other time on
the same or on such other date, in any event not later than January&nbsp;13, 2024, as shall be designated in writing by you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Firm
Shares and Additional Shares shall be registered in such names and in such denominations as you shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The
Firm Shares and Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the case may be, for the respective accounts of the several Underwriters, with any transfer taxes payable in connection with the transfer
of the Shares to the Underwriters duly paid, against payment of the Purchase Price therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<I>Covenants of
the Company</I>. The Company covenants with each Underwriter as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company will (i)&nbsp;prepare and
timely file with the Commission under Rule 424(b) under the Securities Act a Prospectus in a form approved by the Representatives containing information previously omitted at the time of effectiveness of the Registration Statement in reliance on
Rules 430A, 430B or 430C under the Securities Act, and (ii)&nbsp;not file any amendment to the Registration Statement or any documents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incorporated by reference therein or distribute an amendment or supplement to the Time of Sale Prospectus or the Prospectus of which the Representatives shall not previously have been advised and
furnished with a copy or to which the Representatives shall have reasonably objected in writing or which is not in compliance with the rules and regulations of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company will (i)&nbsp;not make any offer relating to the Shares that would constitute an Issuer Free Writing
Prospectus or that would otherwise constitute a &#147;free writing prospectus&#148; (as defined in Rule 405 under the Securities Act) required to be filed by the Company with the Commission under Rule 433 under the Securities Act unless the
Representatives approve its use in writing prior to first use (each, a &#147;<B>Permitted Free Writing Prospectus</B>&#148;); <I>provided</I> that the prior written consent of the Representatives hereto shall be deemed to have been given in respect
of the Issuer Free Writing Prospectus(es) included on <U>Schedule II</U> hereto, (ii)&nbsp;treat each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus, (iii)&nbsp;comply with the requirements of Rules 164 and 433 under the
Securities Act applicable to any Issuer Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending and record keeping and (iv)&nbsp;not take any action that would result in an Underwriter or the
Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Company will advise the Representatives promptly (i)&nbsp;when any post-effective amendment to
the Registration Statement shall have become effective, (ii)&nbsp;of receipt of any comments from the Commission, (iii)&nbsp;when any supplement to the Prospectus, any Issuer Free Writing Prospectus, or any amendment to the Prospectus has been
filed, (iv)&nbsp;of any request of the Commission for amendment of the Registration Statement or for supplement to the Time of Sale Prospectus or the Prospectus or for any additional information, (v)&nbsp;of the issuance by the Commission of any
stop order suspending the effectiveness of the Registration Statement or any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus, or the Prospectus, or of the institution of any proceedings for
that purpose or pursuant to Section&nbsp;8A of the Securities Act, (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period (as defined below) as a result of which the Prospectus, the Time of Sale Prospectus or
any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing
when the Prospectus, the Time of Sale Prospectus or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading, and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification
of the Shares for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any order, suspension or
qualification referred to in clause (v)&nbsp;or (vii) of this paragraph and to obtain as soon as possible the lifting thereof, if issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company will cooperate with the Representatives in
endeavoring to qualify the Shares for sale under the securities laws of such jurisdictions as the Representatives may reasonably have designated in writing and will make such applications, file such documents, and furnish such information as may be
reasonably required for that purpose; <I>provided</I> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation, (ii)&nbsp;file a general consent to service of process in any jurisdiction where it is not now so qualified or
required to file such a consent, or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. The Company will, from time to time, prepare and file such statements, reports, and other documents, as are or may
be required to continue such qualifications in effect for so long a period as the Representatives may reasonably request for distribution of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company will deliver to, or upon the order of, the Representatives, from time to time, as many copies of any
Preliminary Prospectus as the Representatives may reasonably request. The Company will deliver to, or upon the order of, the Representatives, from time to time, as many copies of any Issuer Free Writing Prospectus<B> </B>as the Representatives may
reasonably request. The Company will deliver to, or upon the order of, the Representatives during the period when delivery of a Prospectus (or, in lieu thereof, the notice referred to under Rule 173(a) under the Securities Act) (the
&#147;<B>Prospectus Delivery Period</B>&#148;) is required under the Securities Act, as many copies of the Prospectus in final form, or as thereafter amended or supplemented, as the Representatives may reasonably request. If requested, the Company
will deliver to the Representatives at or before the Closing Date, four signed copies of the Registration Statement and all amendments thereto including all exhibits filed therewith, and will deliver to the Representatives such number of copies of
the Registration Statement (including such number of copies of the exhibits filed therewith that may reasonably be requested), and of all amendments thereto, as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company will comply with the Securities Act and the rules and regulations of the Commission promulgated
thereunder, and the Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Shares as contemplated in this Agreement and the Prospectus. If during the period in which a
prospectus (or, in lieu thereof, the notice referred to under Rule 173(a) under the Securities Act) is required by law to be delivered by an Underwriter or dealer, any event or development shall occur as a result of which, in the judgment of the
Company or in the opinion of the Underwriters, it becomes necessary to amend or supplement the Prospectus in order to make the statements therein, in the light of the circumstances existing at the time the Prospectus is delivered to a purchaser, not
misleading, or, if it is necessary at any time to amend or supplement the Prospectus to comply with any law, the Company promptly will prepare and file with the Commission an appropriate amendment to the Registration Statement or supplement to the
Prospectus so that the Prospectus as so amended or supplemented will not, in the light of the circumstances when it is so delivered, be misleading, or so that the Prospectus will comply with the law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;If the Time of Sale Prospectus is being used to solicit offers to
buy the Shares at a time when the Prospectus is not yet available to prospective purchasers and any event or development shall occur or condition shall exist as a result of which, in the judgment of the Company or in the opinion of the Underwriters,
it becomes necessary to amend or supplement the Time of Sale Prospectus in order to make the statements therein, in the light of the circumstances, not misleading, or to make the statements therein not conflict with the information contained in the
Registration Statement then on file, or if it is necessary at any time to amend or supplement the Time of Sale Prospectus to comply with any law, the Company promptly will prepare, file with the Commission (if required) and furnish to the
Underwriters and any dealers an appropriate amendment or supplement to the Time of Sale Prospectus so that the Time of Sale Prospectus as so amended or supplemented will not, in the light of the circumstances, be misleading or conflict with the
Registration Statement then on file, or so that the Time of Sale Prospectus will comply with law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Company
will make generally available to its security holders, as soon as it is practicable to do so, but in any event not later than 15 months after the effective date of the Registration Statement, an earnings statement (which need not be audited) in
reasonable detail, covering a period of at least 12 consecutive months beginning after the effective date of the Registration Statement, which earnings statement shall satisfy the requirements of Section&nbsp;11(a) of the Securities Act and Rule 158
under the Securities Act and will advise you in writing when such statement has been so made available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Closing Date, the Company will furnish to the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period
covered by the most recent financial statements appearing in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;No offering, pledge, sale, contract to sell, short sale or other disposition of any shares of Common Stock or other
securities convertible into or exchangeable or exercisable for shares of Common Stock or derivative of Common Stock (or agreement for such) will be made for a period of 60 days after the date of the Prospectus, directly or indirectly, by the Company
otherwise than hereunder or with the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC, <I>provided</I>, <I>however</I>, that the Company may (i)&nbsp;effect the transactions contemplated hereby,
(ii)&nbsp;issue shares of Common Stock pursuant to the exercise of warrants outstanding as of the date hereof and described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders of such shares or
warrants agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such shares or warrants during the <FONT STYLE="white-space:nowrap">60-day</FONT> restricted period, (iii)&nbsp;issue shares of its Common Stock
or options to purchase shares of Common Stock, or issue shares of Common Stock upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, but only if the holders of such shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such shares or options during the
<FONT STYLE="white-space:nowrap">60-day</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restricted period and (iv)&nbsp;issue shares or Related Securities (as defined below) in connection with a licensing arrangement, joint venture, acquisition or business combination or other
collaboration or strategic transaction (including the filing of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or other appropriate form with respect thereto); <I>provided that</I>, in the case of clause (iv),
recipients of such shares or Related Securities agree to be bound by the terms of the lockup agreement in the form of <U>Exhibit A</U> hereto and the sum of the aggregate number of Shares or Related Securities so issued shall not exceed 5% of the
total outstanding shares of Common Stock. For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into
Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;The Company will use its best efforts to maintain the listing of the Common Stock on the Nasdaq Global Select
Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;The Company has caused each officer and director and the specific stockholders set forth on
<U>Schedule IV</U> hereto of the Company to execute and deliver to you, on or prior to the date of this agreement, a letter or letters, substantially in the form attached hereto as <U>Exhibit A</U> (the &#147;<B>Lockup Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall apply the net proceeds of its sale of the Shares as set forth in the Registration Statement, the
Time of Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not invest, or otherwise use the proceeds
received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the 1940 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;The Company will maintain a transfer agent and, if necessary under the jurisdiction of incorporation of the
Company, a registrar for the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;The Company will not take, directly or indirectly, any action
designed to cause or result in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<I>Covenants of the Underwriters</I>. Each Underwriter severally covenants with the Company not to take any action
that would result in the Company being required to file with the Commission under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not be required to be filed by the Company thereunder, but for
the action of the Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<I>Costs and Expenses</I>. The Company will pay all costs, expenses and fees
incident to the performance of the obligations of the Company under this Agreement, including, without limiting the generality of the foregoing, the following: (i)&nbsp;accounting fees of the Company; (ii)&nbsp;the fees and disbursements of counsel
for the Company; (iii)&nbsp;all costs and expenses related to the transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes payable thereon; (iv)&nbsp;any roadshow expenses, <I>provided</I>, <I>however</I>, that
the Underwriters and the Company agree that the Underwriters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be responsible for the payment of the Underwriters&#146; food and lodging expenses and fifty percent (50%) of the cost of aircraft and other transportation chartered in connection with the
road show, to the extent applicable; (v)&nbsp;the cost of printing and delivering to, or as requested by, the Underwriters copies of the Registration Statement, Preliminary Prospectuses, the Issuer Free Writing Prospectuses, the Prospectus, this
Agreement, the listing application, any Blue Sky survey, in each case, any supplements or amendments thereto; (vi)&nbsp;the filing fees of the Commission; (vii)&nbsp;the filing fees and expenses (including legal fees and disbursements of counsel for
the Underwriters in an amount not to exceed $25,000) incident to securing any required review by FINRA of the terms of the sale of the Shares; (viii)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Global
Select Market; (ix)&nbsp;the cost of printing certificates, if any, representing the Shares; (x)&nbsp;the costs and charges of any transfer agent, registrar or depositary; (xi)&nbsp;the costs and expenses (including without limitation any damages or
other amounts payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Shares made by the Underwriters caused by a breach of the representation in
<U>Section</U><U></U><U>&nbsp;1(b)</U> hereof; and (xii)&nbsp;and the expenses, including the fees and disbursements of counsel for the Underwriters, incurred in connection with the qualification of the Shares under foreign or state securities or
Blue Sky laws and the preparation, printing and distribution of a Blue Sky memorandum (including the related fees and expenses of counsel for the Underwriters) in an amount not to exceed $15,000. The Company shall not, however, be required to pay
for any of the Underwriter&#146;s expenses (other than those related to qualification under FINRA regulation and state securities or Blue Sky laws) except that, if this Agreement shall not be consummated because the conditions in
<U>Section</U><U></U><U>&nbsp;8</U> hereof are not satisfied, or because this Agreement is terminated by the Representatives pursuant to <U>Section</U><U></U><U>&nbsp;12</U> hereof (other than subclauses (ii), (iii), (v) or (viii)&nbsp;of subsection
(a)&nbsp;of Section&nbsp;12), or by reason of any failure, refusal or inability on the part of the Company to perform any undertaking or satisfy any condition of this Agreement or to comply with any of the terms hereof on its part to be performed,
unless such failure, refusal or inability is due primarily to the default or omission of any Underwriter, the Company shall reimburse the several Underwriters for reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including fees and disbursements of counsel, reasonably incurred in connection with investigating, marketing and proposing to market the Shares
or in contemplation of performing their obligations hereunder; but the Company shall not in any event be liable to any of the several Underwriters for damages on account of loss of anticipated profits from the sale by them of the Shares. Except as
provided in this <U>Section</U><U></U><U>&nbsp;7</U>, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<I>Conditions of Obligations of the Underwriters</I>. The several
obligations of the Underwriters to purchase the Firm Shares on the Closing Date and the Additional Shares, if any, on the Option Closing Date are subject to the accuracy, as of the Applicable Time, the Closing Date or the Option Closing Date, as the
case may be, of the representations and warranties of the Company contained herein, and to the performance by the Company of its covenants and obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement and all post-effective amendments thereto shall have become and remain effective and the
Prospectus and each Issuer Free Writing Prospectus required shall have been filed as required by Rules 424, 430B or 433 under the Securities Act, as applicable, within the time period prescribed by, and in compliance with, the rules and regulations
of the Securities Act, and any request of the Commission for additional information (to be included in the Registration Statement or otherwise) shall have been disclosed to the Representatives and complied with to their reasonable satisfaction. No
stop order suspending the effectiveness of the Registration Statement, as amended from time to time, shall have been issued and no proceedings for that purpose or pursuant to Section&nbsp;8A under the Securities Act shall have been taken or, to the
knowledge of the Company, shall be contemplated or threatened by the Commission and no injunction, restraining order or order of any nature by a federal or state court of competent jurisdiction shall have been issued as of the Closing Date which
would prevent the issuance of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Representatives shall have received on the Closing Date or the
Option Closing Date, as the case may be, the opinion and negative assurance letter of Cooley LLP, counsel for the Company, dated the Closing Date or the Option Closing Date, as the case may be, addressed to the Underwriters (and stating that it may
be relied upon by counsel to the Underwriters) in form and substance satisfactory to the Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The
Representatives shall have received on the Closing Date or the Option Closing Date, as the case may be, the opinion of Cooley LLP, intellectual property counsel for the Company, dated the Closing Date or the Option Closing Date, as the case may be,
addressed to the Underwriters (and stating that it may be relied upon by counsel to the Underwriters) in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Representatives shall have received from Paul Hastings LLP, counsel for the Underwriters, an opinion and the
negative assurance letter, dated the Closing Date or the Option Closing Date, as the case may be, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they
may reasonably request to enable them to pass upon such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Representatives shall have received, on
each of the date hereof, the Closing Date and, if applicable, the Option Closing Date, a letter dated the date hereof, the Closing Date or the Option Closing Date, as the case may be, in form and substance satisfactory to them, of
Deloitte&nbsp;&amp; Touche LLP confirming that they are an independent registered public accounting firm with respect to the Company and the subsidiaries within the meaning of the Securities Act and the applicable rules and regulations and the PCAOB
and stating that in their opinion the financial statements and schedules examined by them and included in the Registration Statement, the Time of Sale Prospectus and the Prospectus comply in form in all material respects with the applicable
accounting requirements of the Securities Act and the related rules and regulations; and containing such other statements and information as is ordinarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the
financial statements and certain financial and statistical information contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Representatives shall have received on the Closing Date and,
if applicable, the Option Closing Date, as the case may be, a certificate or certificates of the Chief Executive Officer and the Chief Financial Officer of the Company to the effect that, as of the Closing Date or the Option Closing Date, as the
case may be, each of them severally represents as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement is effective under the
Securities Act and no stop order suspending the effectiveness of the Registration Statement or no order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus has been issued, and no
proceedings for such purpose or pursuant to Section&nbsp;8A of the Securities Act have been taken or are, to his or her knowledge, contemplated or threatened by the Commission; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Company contained in <U>Section</U><U></U><U>&nbsp;1</U> hereof are
true and correct as of the Closing Date or the Option Closing Date, as the case may be; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;All filings
required to have been made pursuant to Rules 424, 430A, 430B or 430C under the Securities Act have been made as and when required by such rules; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;He or she has carefully examined the Time of Sale Prospectus and any individual Limited Use Free Writing
Prospectus and, in his or her opinion, as of the Applicable Time, the statements contained in the Time of Sale Prospectus and any individual Limited Use Free Writing Prospectus did not contain any untrue statement of a material fact, and such Time
of Sale Prospectus and any individual Limited Use Free Writing Prospectus, when considered together with the Time of Sale Prospectus, did not omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;He or she has carefully examined the Registration
Statement and, in his or her opinion, as of the effective date of the Registration Statement, the Registration Statement and any amendments thereto did not contain any untrue statement of a material fact and did not omit to state a material fact
necessary in order to make the statements therein not misleading, and since the effective date of the Registration Statement, no event has occurred which should have been set forth in a supplement to or an amendment of the Prospectus which has not
been so set forth in such supplement or amendment; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;He or she has carefully examined the Prospectus and,
in his or her opinion, as of its date and the Closing Date or the Option Closing Date, as the case may be, the Prospectus and any amendments and supplements thereto did not contain any untrue statement of a material fact and did not omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;Since the respective dates as of which information is given in
the Registration Statement, the Time of Sale Prospectus and Prospectus, there has not been a Material Adverse Effect, whether or not arising in the ordinary course of business; subsequent to the execution and delivery of this Agreement and prior to
the Closing Date, there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the
rating accorded any of the securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act, and there shall not have
occurred any change, or any development involving a prospective change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Time of
Sale Prospectus that, in your judgment, is material and adverse and that makes it, in your judgment, impracticable to market the Shares on the terms and in the manner contemplated in the Time of Sale Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Representatives shall have received on the Closing Date and, if applicable, the Option Closing Date, as the
case may be, a certificate or certificates of the Chief Financial Officer of the Company, in form and substance satisfactory to the Representatives, with respect to certain financial information contained in the Registration Statement, the Time of
Sale Prospectus and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have furnished to the Representatives such further
certificates and documents confirming the representations and warranties, covenants and conditions contained herein and related matters as the Representatives may reasonably have requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;The Firm Shares and Additional Shares, if any, have been approved for quotation upon notice of issuance on the
Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;The Lockup Agreements described in <U>Section</U><U></U><U>&nbsp;5(l)</U> hereof
are in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;No action shall have been taken and no statute, rule, regulation or order shall
have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Option Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company;
and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Option Closing Date, as the case may be, prevent the issuance or sale of the Shares by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions and certificates mentioned in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in
all material respects satisfactory to the Representatives and to Paul Hastings LLP, counsel for the Underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the conditions hereinabove provided for in this
<U>Section</U><U></U><U>&nbsp;8</U> shall not have been fulfilled when and as required by this Agreement to be fulfilled, the obligations of the Underwriters hereunder may be terminated by the Representatives by notifying the Company of such
termination in writing or by telegram at or prior to the Closing Date or the Option Closing Date, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such event, the
Company and the Underwriters shall not be under any obligation to each other (except to the extent provided in <U>Sections 7</U> and <U>9</U> hereof). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnity and Contribution.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;to indemnify and hold harmless each Underwriter, the directors, officers and employees of each Underwriter and
each person, if any, who controls any Underwriter within the meaning of either Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, and each of their respective affiliates, against any losses, claims, damages or liabilities
to which such Underwriter or any such controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of or are based upon
(i)&nbsp;any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus or any amendment or supplement thereto, or any
road show as defined in Rule 433(h) under the Securities Act (a &#147;<B>road show</B>&#148;), (ii) with respect to the Registration Statement or any amendment or supplement thereto, the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading or (iii)&nbsp;with respect to any Preliminary Prospectus, any Issuer Free Writing Prospectus, or road show, the Prospectus or any amendment or supplement
thereto, the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made; <I>provided</I>,
<I>however</I>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement, or omission or alleged omission made in
the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus, or such amendment or supplement, in reliance upon and in conformity with written information furnished to the Company by or through the
Representatives specifically for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in <U>Section</U><U></U><U>&nbsp;14</U> hereof; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to reimburse each Underwriter, each Underwriters&#146; directors, officers, employees and affiliates, and each
such controlling person upon demand for any legal or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred by such Underwriter or such controlling person in connection with
investigating or defending any such loss, claim, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damage or liability, action or proceeding or in responding to a subpoena or governmental inquiry related to the offering of the Shares, whether or not such Underwriter or controlling person is a
party to any action or proceeding. In the event that it is finally judicially determined that the Underwriters were not entitled to receive payments for legal and other expenses pursuant to this subparagraph, the Underwriters will promptly return
all sums that had been advanced pursuant hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter severally and not jointly will indemnify and
hold harmless the Company, each of its directors, each of its officers who have signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act, against any losses, claims, damages or
liabilities to which the Company or any such director, officer, or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof)
arise out of or are based upon (i)&nbsp;any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus or any amendment or
supplement thereto, (ii)&nbsp;with respect to the Registration Statement or any amendment or supplement thereto, the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading or (iii)&nbsp;with respect to any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus or any amendment or supplement thereto, the omission or alleged omission to state therein a material fact required to
be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made; and will reimburse any legal or other expenses reasonably incurred by the Company or any such director,
officer or controlling person in connection with investigating or defending any such loss, claim, damage, liability, action or proceeding; <I>provided</I>, <I>however</I>, that each Underwriter will be liable in each case to the extent, but only to
the extent, that such untrue statement or alleged untrue statement or omission or alleged omission has been made in the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus<B>, </B>the Prospectus or such amendment
or supplement, in reliance upon and in conformity with written information furnished to the Company by or through the Representatives specifically for use therein, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in <U>Section</U><U></U><U>&nbsp;14</U> hereof. This indemnity agreement will be in addition to any liability which such Underwriter may otherwise have. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In case any proceeding (including any governmental investigation) shall be instituted involving any person in
respect of which indemnity may be sought pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, such person (the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be sought (the
&#147;<B>indemnifying party</B>&#148;) in writing. No indemnification provided for in <U>Section</U><U></U><U>&nbsp;9(a)</U> or <U>(b)</U>&nbsp;hereof shall be available to any party who shall fail to give notice as provided in this
<U>Section</U><U></U><U>&nbsp;9(c)</U> if the party to whom notice was not given was unaware of the proceeding to which such notice would have related and was materially prejudiced (through the forfeiture of substantive rights or defenses) by the
failure to give such notice, but the failure to give such notice shall not relieve the indemnifying party or parties from any liability which it or they may have to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnified party for contribution or otherwise than on account of the provisions of <U>Section</U><U></U><U>&nbsp;9(a)</U> or <U>(b)</U>&nbsp;hereof. In case any such proceeding shall be brought
against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party
similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party and shall pay as incurred the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party
shall have the right to retain its own counsel at its own expense. Notwithstanding the foregoing, the indemnifying party shall pay as incurred (or within 30 days of presentation) the fees and expenses of the counsel retained by the indemnified party
in the event (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii)&nbsp;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying
party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or (iii)&nbsp;the indemnifying party shall have failed to assume the defense
and employ counsel acceptable to the indemnified party within a reasonable period of time after notice of commencement of the action. Such firm shall be designated in writing by you in the case of parties indemnified pursuant to
<U>Section</U><U></U><U>&nbsp;9(a)</U> or <U>(b)</U>&nbsp;hereof and by the Company in the case of parties indemnified pursuant to <U>Section</U><U></U><U>&nbsp;9(b)</U> hereof. The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of
such settlement or judgment. In addition, the indemnifying party will not, without the prior written consent of the indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or
proceeding of which indemnification may be sought hereunder (whether or not any indemnified party is an actual or potential party to such claim, action or proceeding) unless such settlement, compromise or consent (i)&nbsp;includes an unconditional
release of each indemnified party from all liability arising out of such claim, action or proceeding and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.
If at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of any proceeding effected
without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement
at least 30&nbsp;days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;To the extent the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;9</U> is unavailable to or
insufficient to hold harmless an indemnified party under <U>Section</U><U></U><U>&nbsp;9(a)</U> or <U>(b)</U>&nbsp;hereof in respect of any losses, claims, damages or liabilities (or actions or proceedings in respect thereof) referred to therein,
then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) in such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Shares. If, however, the
allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not
only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions or
proceedings in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the net proceeds
from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative
fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one
hand or the Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this
<U>Section</U><U></U><U>&nbsp;9(d)</U> were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations
referred to above in this <U>Section</U><U></U><U>&nbsp;9(d)</U>. The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions or proceedings in respect thereof) referred to above in this
<U>Section</U><U></U><U>&nbsp;9(d)</U> shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of
this <U>Section</U><U></U><U>&nbsp;9(d)</U>, (i) no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions applicable to the Shares purchased by such Underwriter and (ii)&nbsp;no person guilty
of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this
<U>Section</U><U></U><U>&nbsp;9(d)</U> to contribute are several in proportion to their respective underwriting obligations and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;In any proceeding relating to the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing
Prospectus, the Prospectus or any supplement or amendment thereto, each party against whom contribution may be sought under this <U>Section</U><U></U><U>&nbsp;9</U> hereby consents to the exclusive jurisdiction of (i)&nbsp;the federal courts of the
United States of America located in the City and County of New York, Borough of Manhattan and (ii)&nbsp;the courts of the State of New York located in the City and County of New York, Borough of Manhattan, agrees that process issuing from such
courts may be served upon it by any other contributing party and consents to the service of such process and agrees that any other contributing party may join it as an additional defendant in any such proceeding in which such other contributing
party is a party. The Company irrevocably appoints Cooley LLP as its agent to receive service of process or other legal summons for purposes of any such suit, action or proceeding that may be instituted in any state or federal court in the City and
County of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Any losses, claims, damages, liabilities or expenses for which an
indemnified party is entitled to indemnification or contribution under this <U>Section</U><U></U><U>&nbsp;9</U> shall be paid by the indemnifying party to the indemnified party as such losses, claims, damages, liabilities or expenses are incurred.
The indemnity and contribution agreements contained in this <U>Section</U><U></U><U>&nbsp;9</U> and the representations and warranties of the Company set forth in this Agreement shall remain operative and in full force and effect, regardless of
(i)&nbsp;any investigation made by or on behalf of any Underwriter, its directors, officers, employees or any person controlling any Underwriter, the Company, its directors, officers, employees or any persons controlling the Company,
(ii)&nbsp;acceptance of any Shares and payment therefor hereunder, and (iii)&nbsp;any termination of this Agreement. A successor to any Underwriter, its directors or officers or any person controlling any Underwriter, or to the Company, its
directors, officers, employees or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement agreements contained in this <U>Section</U><U></U><U>&nbsp;9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<I>Defaulting Underwriters</I>. If on the Closing Date or the Option Closing Date, as the case may be, any
Underwriter shall fail to purchase and pay for the portion of the Shares which such Underwriter has agreed to purchase and pay for on such date (otherwise than by reason of any default on the part of the Company), you, as Representatives of the
Underwriters, shall use your reasonable efforts to procure within 36 hours thereafter one or more of the other Underwriters, or any others, to purchase from the Company such amounts as may be agreed upon and upon the terms set forth herein, the
Shares which the defaulting Underwriter or Underwriters failed to purchase. If during such 36 hours you, as such Representatives, shall not have procured such other Underwriters, or any others, to purchase the Shares agreed to be purchased by the
defaulting Underwriter or Underwriters, then (a)&nbsp;if the aggregate number of shares with respect to which such default shall occur does not exceed 10% of the Shares to be purchased on the Closing Date or the Option Closing date, as the case may
be, the other Underwriters shall be obligated, severally, in proportion to the respective numbers of Shares which they are obligated to purchase hereunder, to purchase the Shares which such defaulting Underwriter or Underwriters failed to purchase,
or (b)&nbsp;if the aggregate number of shares of Shares with respect to which such default shall occur exceeds 10% of the Shares to be purchased on the Closing Date or the Option Closing Date, as the case may be, the Company or you as the
Representatives of the Underwriters will have the right, by written notice given within the next <FONT STYLE="white-space:nowrap">36-hour</FONT> period to the parties to this Agreement, to terminate this Agreement without liability on the part of
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or of the Company except to the extent provided in <U>Sections 7</U> and <U>9</U> hereof. In the event of a default by any Underwriter or Underwriters, as set forth in this
<U>Section</U><U></U><U>&nbsp;10</U>, the Closing Date or Option Closing Date, as the case may be, may be postponed for such period, not exceeding seven days, as you, as Representatives, may determine in order that the required changes in the
Registration Statement, the Time of Sale Prospectus or in the Prospectus or in any other documents or arrangements may be effected. The term &#147;Underwriter&#148; includes any person substituted for a defaulting Underwriter. Any action taken under
this <U>Section</U><U></U><U>&nbsp;10</U> shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices</I>. All communications hereunder shall be in writing
and, except as otherwise provided herein, will be mailed, delivered, telecopied or telegraphed and confirmed as follows: if to the Underwriters, to Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282, Attention: Registration
Department; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attention: Equity Syndicate Desk; and Cowen and Company, LLC, 599 Lexington Avenue, 25th Floor, New York, New York 10022, Attention: Bradley Friedman, with a copy
to Paul Hastings LLP, MetLife Building, 200 Park Avenue, New York, New York 10166, Attention: Siavosh Salimi and William A. Magioncalda; if to the Company, to Syndax Pharmaceuticals, Inc., 35 Gatehouse Drive, Building D, Floor 3, Waltham,
Massachusetts 02451, Attention: Luke Albrecht, fax number: (781) <FONT STYLE="white-space:nowrap">419-1420,</FONT> with a copy to Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304, Attention: Laura Berezin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination</I>. This Agreement may be terminated by you by notice to the Company (a)&nbsp;at any time prior to
the Closing Date or any Option Closing Date (if different from the Closing Date and then only as to Additional Shares) if any of the following has occurred: (i)&nbsp;since the respective dates as of which information is given in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, any material adverse change or any development involving a prospective material adverse change in or affecting the earnings, business, management, properties, assets, rights, operations,
condition (financial or otherwise) or prospects of the Company and the subsidiaries taken as a whole, whether or not arising in the ordinary course of business; (ii)&nbsp;any outbreak or escalation of hostilities or declaration of war or national
emergency or other national or international calamity or crisis (including, without limitation, an act of terrorism) or change in economic or political conditions if the effect of such outbreak, escalation, declaration, emergency, calamity, crisis
or change on the financial markets of the United States would, in your judgment, materially impair the investment quality of the Shares; (iii)&nbsp;suspension of trading in securities generally on the New York Stock Exchange, the American Stock
Exchange or the Nasdaq Stock Market or limitation on prices (other than limitations on hours or numbers of days of trading) for securities on any such exchange; (iv)&nbsp;the enactment, publication, decree or other promulgation of any statute,
regulation, rule or order of any court or other governmental authority which in your opinion materially and adversely affects or may materially and adversely affect the business or operations of the Company; (v)&nbsp;the declaration of a banking
moratorium by the United States or New York State and other jurisdictions as applicable authorities; (vi)&nbsp;any downgrading, or placement on any watch list for possible downgrading, in the rating of any of the Company&#146;s debt securities or
preferred stock by any &#147;nationally recognized statistical rating organization&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act) or any public announcement by such organization
that it has under surveillance or review, or has changed its outlook with respect to, its rating of any such debt securities or preferred stock (other than an announcement with positive implications of a possible upgrading); (vii) the suspension of
trading of the Company&#146;s Common Stock by the Nasdaq Global Select Market, the Commission or any other governmental authority; or (viii)&nbsp;the taking of any action by any governmental body or agency in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect of its monetary or fiscal affairs which in your opinion has a material adverse effect on the securities markets in the United States; or (b)&nbsp;as provided in <U>Sections 8</U> and
<U>10</U> of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<I>Successors</I>. This Agreement has been and is made solely for the benefit of
the Underwriters and the Company and their respective successors, executors, administrators, heirs and assigns, and the officers, directors and controlling persons referred to herein, and no other person will have any right or obligation hereunder.
No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign merely because of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<I>Information Provided By Underwriters</I>. The Company and the Underwriters acknowledge and agree that the only
information furnished or to be furnished by any Underwriter to the Company for inclusion in the Registration Statement, any Preliminary Prospectus, any Issuer Free Writing Prospectus, or the Prospectus consists of the information set forth in the
third and twelfth paragraphs under the caption &#147;Underwriters&#148; in the Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<I>Entire
Agreement</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; This Agreement, together with any contemporaneous written agreements and any prior written
agreements (to the extent not superseded by this Agreement) that relate to the offering of the Shares, represents the entire agreement between the Company and the Underwriters with respect to the preparation of any preliminary prospectus, the Time
of Sale Prospectus, the Prospectus, the conduct of the offering, and the purchase and sale of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges that in connection with the offering of the Shares: (i)&nbsp;the Underwriters have acted at arm&#146;s length, are not agents of, and owe no fiduciary duties to, the Company or any other person, (ii)&nbsp;the Underwriters owe
the Company only those duties and obligations set forth in this Agreement and prior written agreements (to the extent not superseded by this Agreement), if any, and (iii)&nbsp;the Underwriters may have interests that differ from those of the
Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Underwriters arising from an alleged breach of fiduciary duty in connection with the offering of the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts</I>. This Agreement may be signed in two or more counterparts, each of which shall be an original,
with the same effect as if the signatures thereto and hereto were upon the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;<I>Applicable Law</I>. This Agreement shall be governed by, and
construed in accordance with, the law of the State of New York, including, without limitation, <FONT STYLE="white-space:nowrap">Section&nbsp;5-1401</FONT> of the New York General Obligations Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings</I>. The headings of the sections of this Agreement have been inserted for convenience of reference
only and shall not be deemed a part of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;<I>Miscellaneous</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The reimbursement, indemnification and contribution agreements contained in this Agreement and the representations,
warranties and covenants in this Agreement shall remain in full force and effect regardless of (a)&nbsp;any termination of this Agreement, (b)&nbsp;any investigation made by or on behalf of any Underwriter or controlling person thereof, or by or on
behalf of the Company or its directors or officers, and (c)&nbsp;delivery of and payment for the Shares under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that each Underwriter in providing investment banking services to the Company
in connection with the offering, including in acting pursuant to the terms of this Agreement, has acted and is acting as an independent contractor and not as a fiduciary and the Company does not intend such Underwriter to act in any capacity other
than as an independent contractor, including as a fiduciary or in any other position of higher trust.<B> </B>Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax,
investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with their own advisors concerning such matters and shall be responsible for making their own independent investigation and appraisal of the transactions
contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such
transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. The Company agrees and acknowledges that the Underwriters have not provided any recommendation or investment advice with respect to
the transactions contemplated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Underwriters, on the one hand, and the Company (on its own behalf
and, to the extent permitted by law, on behalf of its stockholders), on the other hand, waive any right to trial by jury in any action, claim, suit or proceeding with respect to your engagement as underwriter or your role in connection herewith.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter is a Covered Entity and becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if
this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter is a Covered Entity or a BHC
Act Affiliate of such Underwriter and becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than
such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;20: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance
with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covered Entity</B>&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as
that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;382.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Right</B>&#148; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">SYNDAX PHARMACEUTICALS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Luke Albrecht</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Luke Albrecht</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acting severally on behalf of themselves and the several Underwriters named in Schedule&nbsp;I hereto.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">GOLDMAN SACHS&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Danielle Freeman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Danielle Freeman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Ke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Ke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">COWEN AND COMPANY, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bill Follis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bill Follis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE&nbsp;I </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Firm<BR>Shares To Be<BR>Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,783,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,243,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,162,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,513,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B. Riley Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,810,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE&nbsp;II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Time of Sale Prospectus </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary
Prospectus issued December&nbsp;14, 2023 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Firm Shares Offered by Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">10,810,810 shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Additional Shares Offered by Company:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1,621,621 shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Price to Public:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$18.50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trade Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;15, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;19, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CUSIP No:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">87164F105</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE&nbsp;III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Subsidiaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndax Securities Corporation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndax Limited </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Syndax Europe B.V. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">III-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>SCHEDULE IV </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stockholders Subject to Lockup </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael
A. Metzger </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keith A. Goldan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil Gallagher </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Madigan, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Ordentlich, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Briggs W. Morrison, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dennis G. Podlesak </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keith A. Katkin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pierre Legault </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William Meury </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Martin Huber </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve Sabus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IV-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Attached] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#9679;], 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Syndax Pharmaceuticals, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Goldman Sachs&nbsp;&amp;
Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282-2198 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Cowen and Company, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">599 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that Goldman Sachs&nbsp;&amp; Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives (the &#147;<B>Representatives</B>&#148;) of the several underwriters (the &#147;<B>Underwriters</B>&#148;), propose to enter
into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Syndax Pharmaceuticals, Inc. (the &#147;<B>Company</B>&#148;) relating to the public offering by the Company of an unspecified number of shares of common stock, par
value $0.0001 per share (the &#147;<B>Common Stock</B>&#148;), of the Company (the &#147;<B>Offering</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce the
Underwriters that may participate in the Offering to continue their efforts in connection with the Offering, the undersigned agrees that, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC and J.P. Morgan Securities LLC on behalf
of the Underwriters, the undersigned will not, directly or indirectly, offer, sell, pledge, contract to sell (including any short sale), grant any option to purchase or otherwise transfer or dispose of any shares of Common Stock (including, without
limitation, shares of Common Stock which may be deemed to be beneficially owned by the undersigned currently or hereafter in accordance with the rules and regulations of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;),
shares of Common Stock which may be issued upon exercise of a stock option or warrant and any other security convertible into or exchangeable for Common Stock), enter into any Hedging Transaction (as defined below) relating to the Common Stock (each
of the foregoing referred to as a &#147;<B>Disposition</B>&#148;), or publicly announce any intention to do so, during the period commencing </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the date hereof and continuing until, and including, the date that is sixty (60)&nbsp;days after the date of the final prospectus relating to the Offering (the &#147;<B><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</B>&#148;). The foregoing restriction is expressly intended to preclude the undersigned from engaging in any Hedging Transaction or other transaction which is designed to or reasonably expected to
lead to or result in a Disposition during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period even if the securities would be disposed of by someone other than the undersigned. &#147;<B>Hedging Transaction</B>&#148; means any short sale
(whether or not against the box) or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any security (other than a broad-based market basket or index) that includes, relates to or derives
any significant part of its value from the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing restrictions shall not apply to the transfer of any or all of the
shares of Common Stock or other Company securities by the undersigned if the transfer does not, except in the case of gifts pursuant to clause (i)&nbsp;below and dispositions pursuant to clause (iv)&nbsp;below, trigger any filing or reporting
requirement or obligation or result in any other voluntary or mandatory public disclosure under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and the transfer is (i)&nbsp;by gift, will
or intestacy, (ii)&nbsp;to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or the family member(s) of the undersigned, (iii)&nbsp;a distribution to partners, members or shareholders of the undersigned, or to any
corporation, partnership or limited liability company that is an affiliate (within the meaning set forth in Rule 405 as promulgated by the Commission under the Securities Act of 1933, as amended) of the undersigned, (iv)&nbsp;in transactions
pursuant to any trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a &#147;<B><FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan</B>&#148;), entered into prior to the date hereof; <I>provided</I>,
<I>however</I>, any required filings required under Section&nbsp;16(a) of the Exchange Act shall disclose by footnote that such transaction was pursuant to a <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan, or (v)&nbsp;to the Company upon the
exercise of options to cover tax withholding obligations in connection with such exercise or for the primary purpose of paying the exercise price of options or warrants to acquire shares of Common Stock in each case pursuant to a stock option, stock
bonus or other stock plan, warrant agreement or other arrangement existing as of the date hereof and any shares acquired shall remain subject to this <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
(&#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</B>&#148;); <I>provided</I>, <I>however</I>, for any transfers pursuant to clauses (i)-(iii) above, it shall be a condition to the transfer that the transferee execute an agreement
stating that the transferee is receiving and holding the securities subject to the provisions of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. In addition, the undersigned may enter into any plan designed to satisfy the
requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of shares of Common Stock or other Company securities, in each case, within the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period); <I>provided</I> <I>however</I>, any public announcement or filing under the Exchange Act regarding the establishment of such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan shall clearly
disclose that no shares of Common Stock shall be disposed by such plan during the duration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the foregoing restrictions shall not apply to, and nothing in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement prohibits (i)&nbsp;the undersigned (or any family member of the undersigned) from exercising any options, warrants or other rights to purchase shares of Common Stock pursuant to any stock option, stock bonus or other stock plan or any
other arrangement existing as of the date hereof (which exercises may be effected on a cashless basis to the extent the instruments representing such options, warrants or other rights permit exercises on a cashless basis) or (ii)&nbsp;the grant by
the Company of stock options or other stock-based awards to the undersigned pursuant to any stock option, stock bonus or other stock plan, warrant </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or other arrangement existing as of the date hereof; <I>provided</I>, <I>however</I>, that in any such case, any shares of Common Stock or other Company securities acquired shall remain
subject to this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; and <I>provided</I> <I>further</I>, that (A)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during
<FONT STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Period</FONT> shall clearly indicate in the footnotes thereto that (1)&nbsp;the filing relates to the circumstances described above and (2)&nbsp;the shares Common Stock continue to be subject to
the restrictions on transfer set forth in this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and (B)&nbsp;the undersigned does not otherwise voluntarily effect any other public filings or reports regarding such exercise during <FONT
STYLE="white-space:nowrap">the&nbsp;Lock-Up&nbsp;Period.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned agrees that the Company may, and that the undersigned
authorizes the Company to, (i)&nbsp;with respect to any shares of Common Stock or other Company securities for which the undersigned is the record holder, cause the transfer agent for the Company to note stop transfer instructions with respect to
such securities on the transfer books and records of the Company and (ii)&nbsp;with respect to any shares of Common Stock or other Company securities for which the undersigned is the beneficial holder but not the record holder, cause the record
holder of such securities to cause the transfer agent for the Company to note stop transfer instructions with respect to such securities on the transfer books and records of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the undersigned hereby waives any and all notice requirements and rights with respect to registration of securities pursuant to
any agreement, understanding or otherwise setting forth the terms of any security of the Company held by the undersigned, including any registration rights agreement to which the undersigned and the Company may be party; <I>provided</I> that such
waiver shall apply only to the proposed Offering, and any other action taken by the Company in connection with the proposed Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned hereby agrees that, to the extent that the terms of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement conflict with or are in any way inconsistent with any registration rights agreement to which the undersigned and the
Company may be a party, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement supersedes such registration rights agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. All authority herein conferred or agreed to be conferred shall survive the
death or incapacity of the undersigned and any obligations of the undersigned shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if (i)&nbsp;the Company notifies the Representatives in writing that it does not intend to
proceed with the Offering prior to the execution of the Underwriting Agreement, (ii)&nbsp;the Underwriting Agreement (other than the provisions thereof which survive termination) is terminated for any reason prior to payment for and delivery of the
shares of Common Stock to be sold thereunder or (iii)&nbsp;the closing of the Offering has not occurred prior to December&nbsp;31, 2023, this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Shares and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The undersigned further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in
connection with the Public Offering, the Underwriters are not making a recommendation to you to participate in the Public Offering or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures or
documentation is intended to suggest that any Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that the Company
and the Underwriters are relying upon this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement in proceeding toward consummation of the offering. The undersigned further understands that this <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement is irrevocable and shall be binding upon the undersigned&#146;s heirs, legal representatives, successors, and assigns. This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall be governed
by, and construed in accordance with, the law of the State of New York, including, without limitation, <FONT STYLE="white-space:nowrap">Section&nbsp;5-1401</FONT> of the New York General Obligations Law. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yours truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Signature</I>:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Print
Name</I>:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d50500dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50500img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jaime L. Chase </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 202 728
7096 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jchase@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;15, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Syndax Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building D, Floor 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">35 Gatehouse Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, Massachusetts 02451 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested our opinion, as
counsel to Syndax Pharmaceuticals, Inc., a Delaware corporation (the&nbsp;&#147;<B>Company</B>&#148;), with respect to certain matters in connection with the offering by the Company of up to 12,432,431 shares (the &#147;<B>Shares</B>&#148;) of its
common stock, par value $0.0001 (&#147;<B>Common Stock</B>&#148;), including up to 1,621,621 Shares that may be sold pursuant to the exercise of an option to purchase additional Shares, pursuant to a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-254661)</FONT> (the &#147;<B>Registration Statement</B>&#148;), filed with the Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Securities </I></B><B>Act</B>&#148;), the prospectus included in the Registration Statement (the &#147;<B>Base Prospectus</B>&#148;), and the prospectus
supplement, dated December&nbsp;14, 2023, and filed with the Commission pursuant to Rule 424(b) under the Securities Act (together with the Base Prospectus, the &#147;<B>Prospectus</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the Company&#146;s certificate of incorporation
and bylaws, each as currently in effect, and such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the
genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials,
and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness of such documents. As to certain factual matters, we have
relied upon a certificate of an officer of the Company and have not independently verified such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion herein is expressed solely with
respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or
state securities law, rule or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and
issued against payment therefor as provided in the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
opinion is limited to the matters expressly set forth in this letter, and no opinion should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof
and we undertake no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;1299 Pennsylvania Avenue, NW&nbsp;&nbsp;&nbsp;&nbsp;Washington, DC&nbsp;&nbsp;&nbsp;&nbsp;20004-2400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (202)
842 7800&nbsp;&nbsp;f: (202) 842 7899&nbsp;&nbsp;cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g50500img1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Syndax Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December 15, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus and to
the filing of this opinion as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed with the Commission for incorporation by reference into the Registration Statement. In giving such consent, we do not
thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>OOLEY</SMALL> LLP </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaime L. Chase</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jaime L. Chase</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley
LLP&nbsp;&nbsp;&nbsp;&nbsp;1299 Pennsylvania Avenue, NW&nbsp;&nbsp;&nbsp;&nbsp;Washington, DC&nbsp;&nbsp;&nbsp;&nbsp;20004-2400 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (202)
842 7800&nbsp;&nbsp;f: (202) 842 7899&nbsp;&nbsp;cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sndx-20231214.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/16/2023 3:24:49 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:sndx="http://www.syndax.com/20231214"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.syndax.com/20231214"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sndx-20231214_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sndx-20231214_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>sndx-20231214_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/16/2023 3:24:49 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>sndx-20231214_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/16/2023 3:24:49 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sndx-20231214.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g50500img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g50500img1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M N4<53<-[H\W^$3.-:U! 3Y9MP2.V0PQ_,URX?XF?3\1)>Q@^M_T./\ $O\
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MG)G>*]OB>1;1T^?7_+Y'95N>(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 >9:EX"UK7?%KZAJ,EN+)YAE5D)81#HHXZX'YFN65&4IW9]50S;#87
M"*E23YDNW7[STQ5"*%4 *!@ =JZCY9N^K%H$% !0 4 % !0 4 % !0 4 % !
70 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140198304325184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Syndax Pharmaceuticals Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001395937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 14,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0162505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">35 Gatehouse Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">419-1400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNDX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d50500d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sndx-20231214.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-14_to_2023-12-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-14</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-12-14_to_2023-12-14"
      id="Hidden_dei_EntityRegistrantName">Syndax Pharmaceuticals Inc</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-12-14_to_2023-12-14">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-14_to_2023-12-14"
      id="Hidden_dei_EntityCentralIndexKey">0001395937</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-14_to_2023-12-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-14_to_2023-12-14">2023-12-14</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-14_to_2023-12-14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-14_to_2023-12-14">001-37708</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-14_to_2023-12-14">32-0162505</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-14_to_2023-12-14">Building D</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-12-14_to_2023-12-14">Floor 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-12-14_to_2023-12-14">35 Gatehouse Drive</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-14_to_2023-12-14">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-14_to_2023-12-14">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-14_to_2023-12-14">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-14_to_2023-12-14">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-14_to_2023-12-14">419-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-12-14_to_2023-12-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-14_to_2023-12-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-14_to_2023-12-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-14_to_2023-12-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-12-14_to_2023-12-14">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-14_to_2023-12-14">SNDX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-14_to_2023-12-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-14_to_2023-12-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *^+CU<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "OBX]7]K )6.T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITE1,'1S43PI""XHWD(RNQMLFI",M/OVIG6WB^@#"+EDYL\W
MWT Z$Z4)"9]3B)C(8;Z:?#]D:>*&'8BB!,CF@%[GNB2&TMR%Y#65:]I#U.9#
M[Q%$T]R 1])6DX896,65R%1GC30)-85TPENSXN-GZA>8-8 ]>APH Z\Y,#5/
MC,>I[^ "F&&$R>?O MJ5N%3_Q"X=8*?DE-V:&L>Q'MLE5W;@\/;T^+*L6[DA
MDQX,EE?923I&W+#SY-?V[G[[P)1H1%MQ4?'KK1!2W);S/KO^\+L(^V#=SOUC
MX[.@ZN#7OU!?4$L#!!0    ( *^+CU>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKSXC$+T2HG<9Q(PK(>UD# E,Z5J>!J7C%&R:@_T2K7])VF L2I5)53@#F1N
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "OBX]7)!Z;HJT
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M2P$"% ,4    " "OBX]7!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *^+CU?VL E8[0   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M *^+CU>97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ KXN/5SWG*9IG!   NA$  !@
M     ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M *^+CU>?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ KXN/5Y>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ KXN/5QPX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *^+
MCU<D'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *^+CU=ED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d50500d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d50500d8k.htm">d50500d8k.htm</File>
    <File>sndx-20231214.xsd</File>
    <File>sndx-20231214_lab.xml</File>
    <File>sndx-20231214_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d50500d8k.htm": {
   "nsprefix": "sndx",
   "nsuri": "http://www.syndax.com/20231214",
   "dts": {
    "inline": {
     "local": [
      "d50500d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "sndx-20231214.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sndx-20231214_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sndx-20231214_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-14_to_2023-12-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50500d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-14_to_2023-12-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d50500d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.syndax.com//20231214/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-296814-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-296814-xbrl.zip
M4$L#!!0    ( *^+CU?9EMSYS!(  $5T   -    9#4P-3 P9#AK+FAT;>T=
M:W/B./+[5NU_4+&[5Z2*APWD11Y76<+,<IM7A4SMW'W9$K8(OC&V5Y(#W*^_
M;DDV!DR A"0SLYF:F6#T:O6[6RWG^)_CH4\>&!=>&)P4[(I5("QP0M<+[D\*
ML>R7#PKDGZ<__G \D- 1.@>BZ3+OI#"0,FI6J^,>]RN".97[\*$*#=6:5:L7
M3,=8E.4D8B+MW:>B5PGY?35IF>D>A$$0#]/.H]&HHJ;' :[D51Q1A4YEZ,6X
MYR3CQKX7?)D9-JJK0?;AX6%5M29=%WJF"]0LJU[%YAX5+.DN G<\TUU, I>.
M*TXX5)#;-;N10B&\/!A@7KOZ^?*BZPS8D):]0$@:..D*L>1+X3FL0FO2T1-A
MHV;O/P*\Z9$.&"_K:T/? +;*/O]Z>S'M+O/[3[M6):>!Z(=\2"6P"\ZT6[9J
MY=I>9I(R,,,LR@QSK)KGH%RW4US"XMYC6YW#(K:Z<TQI.N]5=:/INIQ-D,$+
MBM,9=?&G]*3/3@_*OQ]7]4?X;L@D)3A#F?T5>P\GA5882!;(\AWP9H$X^NFD
M(-E85M6,I(KCJF920LAQ+W0GI\>N]T"$G/CLI.!Z(O+I!/F?%4[)L3=N8G?&
MS6?/=5F@/T.7*\W\Q'-/"K^IIC]![OYL!P#DY);=>P+1*Z_H$  *X']8@'G-
M_'8%\%C>LC[TBKFBQY_(V66[5K8;?\HP\U0X[2KV)S<#"K1S6"P]A_J"= +G
MN#H#W0*T4T#.ABQPX9_\X-/[C2'HPWILU6*YJ&G!DISZG<!EX]_99!$W"QTV
M!,T"2:\?[A[6]Q?AJ\[1D;,^XZ!HF8!GU#I-H?0#K$64PFJBLCLI"&\8^<CF
MZKL!1U!0*943[5,9"S=IIMSA(3+4VOKM!33GZ7%U=C]F]S,[5L\BC+E^5.+>
M-.A6U%L#W<DPIHB7/GHN?M'W&"<*!):KC%J=WV<)-C\8H<Z=/P**AF[Z"'J(
MRW,JV>D4MF3DM&T*J[ND;]*2+INN4YW!3HK-*?:J67U1!;T"/S+:!4>5J>_=
M!TT']L)X8;9]Y+ERT#RH['K!4::OS_KR:$CYO1>4\7.3T%B&R3?<NQ^8KW"Z
M*)D,57QYP%0K.!-1.H4,HV;FL1=*&0[5-[V0 ^C)-W8T)B+T/9?\9*D_A=-_
M_&3O64?'U6C90O75"]6>O%!FV@.8A"QN@/2!-&7A_8\U[8/TN4^'GC]IWGE#
M)L@5&Y';<$B#(]4VTG#W0M\]RB'/IZO.7?N<=._.[MK=Y>!8KP1.M]WZ=-NY
MZ[2[Y.SJG+0_MWX[N_K8)JWKR\M.M]NYOGH6C+5MP/@'%0-P6648E,AYI54A
M-6NW<3@'UW31_348<Y8?5@E4+F/N/8DQ*Q9TF^7-(RVD-?N7Q<VO*:33S20Z
M(H]>^Z_$4Q^N;R_)L8AHD*JA@2=9&;YQ&)C.$:<1F))E/L1YZ,3H0F2\KO7M
MM/+H9@WT<15!.7WGEQ?@EZW(-VB@V_;5';EMWUS?WKV]OKF)N8C!BR8R)%WF
M(,=IA-EU$G)B[Q;=G;>',NP3.6 (8,P]Z<'X]M@9T.">D3-'$FBV#^N-Y7"^
M%G71\T%H;ED4<DF*R3.CX/DP(0E[@)Z$JV;F[C3?'K4K5=.-\M_:VJW;5$<1
M'1R?%""@;KHPP1"&#UPZF0!*6  88PX;]A@W3-<H$1R]J-;>]=FV]5FML0WV
MF;5]!),F96]<UB%B<U58?]K]]]7YV6=R\]O9[>59J_WIKM,ZN^B62.>J53&V
MC#Q+1JQM;++8'E-0,R@;*,T\W02A@HB(.1AIN<0+B"<% <4$PLWGU>8[T^8S
M[3/P@KDMVO,9<9COH\>EDKU603U'U'639[.4V:H3^CZ-!&LF'Q[GD P[H<NH
MD6%;UB\&=4W+@-FTDC@2 >/ZASL;GM8;OV!F0;ISK0^,JQR40:[><&Y/,T]M
M@WD2F/.'S$\(_QG8>=(EHO>LW..,?L&\K^>R)GT(@4'61IRM2#>[+LDP$YGA
MIJ;B(S*W%^ )@#"K;N9E]Q%KIM5/)W!"#K976:VN!'O4"N- \DDK=)]EVU#O
M89I$LHB'#[BL-FX^'8&=6^JEK\L&"<\O]'\1'#XYFM%(_N#Y#-K J#\A\VB7
MZ_O[UL%2C'W/B+NCXX[)VSD*4T_$8KU6MNR]VJZUNP8:7T+:#UY'V(M*X#!,
M"2$ZX.2_$!P(UU-!S'&/DRK&#5Y6Y'?>F(&>ZL9L)551;(7#H2?P@'0CE\I^
M 5A01Q#-WCO:*_@J);K8J=Q6NA72'D9^.&%<<]6LD)*KL+*S(%'P'WHFWZJC
MH_SFK\33J6]I'OMK=W"2+;QML+/"2)VY+F="F!\7$&_8&QNH7V//1Y8EY_,&
MJO3VP=[&^Z]MO/\/?@A&:U66XUO8>WUSYV27? 2K/0ACP<@Y]QX6O./->,!^
M.SRTX.,UOPM'P<98^(/Z<D"'"UM?7FTPL[(*7:[Y#<0:GJH>V7;D<DF%H,X
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MDPO]1BPPGXRM5,,H9OXBS@0 0)%W1&)W!'M090XI.A@7I(@Y-315#\R'*5X
M);!*/B)* *A/%<J 3KBR)]!\.DQM2U"=@[&MTH'^1P3PU70_K<2-,E5DCH[2
M!#KL)5#VG#Q0/V;D9ZN"+S9"DZ]G0+=U2UR8"0OSMT@E2'0$?A1+-AG%/1B-
MF_C9!D-@9>':'OK5N0)F9'+AJH!$8JV5\H5*66PJ/^H>/2I=A8--65*B/(61
M<J&@%1P>\&7 S8HCHF4MF13XS"[MU=2_#-VR**L0#+/ X1/*A7(8 U_*+)E
MT^?A4'V1[ ?K <&AB[2CI[/:JAII[.&YM#\A/]<L(+@6*5!@/H):!&=NOE=]
MH9=Q*F>VR\:,.YYV)#V>M_7,CLT^(7[JQ[X/U-=N!@16+I85 ?0SJLCUA/(F
MA>)W)[U5I9_#9,>XVT P47GD!KM^A\.V-?U=%O$0,/68/O]WV8RKFR>,8L#\
MZ0UWA315'*XT[\K(+?&;L91,?^J6ZTGX5E27OE;.<14:Y[I>KY=KNXV]/7NG
ME,RA,UP]YF *CL$6E08$-@8X37694M-S<2C2)77?I]?@"/R]I, />L&:MH<V
M2#_!5\ A=^/M?AE#C$V1;W,ZJ[EU3..K/IE!(HXB7Z-.C\^WOUJ@L@3+"HKC
MAP * @NRT MC.3_+86+%1=S[+PQ317BJZHXZ29&=$X-Z!3:;J.EP%8A!-?^_
M$7_FFUX5&E-P0C,09\TB@%LB(\I1T0%A2]#_@4&09V0Q=1($QIT9_E8!*1L&
MTUM[TR+$><.44C2K4+*ES1A\^A[M ;\I[DI/( W+Y^9<E(6G0Q70ELR%U1P8
MP/RE' OK#B&"U7%O6ONHN>5I2#'8U;DBN9P*(_##M+X( U"ZN&%0'!$PH@)4
MQ""$4X=,+:(;]+LP',7N"!3. U$A,Y/@DCT6@'\LYS>,3#LS;4G-.Z03-!49
MUO:]H6=VK3N[6OP-P7&+G&JM;>:ND#/?7^9]N!Z'B4.N<35_&<%\#1\0;]I'
M&8 AQX8!A6X:@AG92SJSL<,B0QV3V1 , >$ZH=$W=:[Y5E;A:\\"3$Y$*67)
MK+4WFU]O:C-XR?0(K3HR ZT'B_6!\Y;&"JA?40OU/2Z BCW<J_(%88516B$9
M(&_BPJL<9K6UY3[SVR@GM/[WH;+U3#C<B[+%RBB6*4Z7") ;PJ1(&24V7!J/
M1Z6LF-2.,NIY1/I?,;A^V1?(X.UBSN0$63I]V^B"4S>S8,E81LP<2PFS,B62
M[?' ZX&LV16;@,)A,D3G79DG$S@H0-(K\C!J9DT<XP6O3X,SP%245H"'$7"8
MQG\K!&4R <:X60A"?'8/>)3IJ-R@1,=3*8,9+9@UO7GHVTW1MX"*S+8.GEM4
M]9X/LHX.O^E\T(<TX=Q-G.;$^52<)+:3!GH.T(73HKN3PO,(.]=>NDIH.^R^
M1ID0YGI-J9#YX&H2)$_K%/4LJ2?2C8?U5R[J6;L@)Q&<G)M1:\G'&B4:)'GM
MNWXQ?KGG@W^Q]?(&P[%/*4W9[ ;R=XW%\ZD[,ZN(IC*2HPH6^2^Y4(<M.8C-
M-(,E1V4 R*N]\NLW%LU#;L5:ED? 3WHIYM*5$93H5]^[N]:N9;EL;-N5@1PN
MRT27'LT;E-!90^O28W+$6+ 0Q+Y0LAJ-&%U*R[\CW^R^.M_L&KZYSO.-WPFD
M"KOK;T:5UC3^S40L19U"TH%>)K;8>:>7JB6R&B]*KE8(WY(;V"'IH#6D.G=\
M3B4E*C5=1!WK(GTPQV%BPXXRQP1_W0]$]?J5R%AY-#6<J0^/'Z=U#LJ>_GV+
M'=[T/4;=SL>KL[M/M^WNJZ<N;N8.6#C^?B5N0L'U*N1*>352;NQ/B$-CK&M2
M57#ZG0HFL21@]WAA1">0>FQ _7Z2$57I:=,!LQ@Q'J^KZ8!8@Y##QMS'\AJ;
M!H+'ILKG[:+!QF(PJ#EV:3PXR_K[232W28#XZ*V/P]E;'XO>]BLIWHP5J*_,
MRJSQ<N[GV"QDK,>,EFK_FJQ6X?372?/E7GRUV>V!%=5W&VJM%9Q0->06J_H1
MT_$B_L(@N"!G/I#%&<A7OXGP<B\76])_<<??\VZ35Z_@Z[,%\U6("%:-,TGY
M),\Y>NPE-TL-\48LC+^>PFW.A\J[.E1.?*=Y_^RXJG^)H?H5AZ?_!U!+ P04
M    " "OBX]7P.*I>5.9  "J% , #P   &0U,#4P,&1E>#$Q+FAT;>R]:7,;
MQY(N_!T1_ \=OG,FR(@6S462M8TBJ,4V9V1+(<ESYMPWW@\-H$&V!73C]$(*
MY]??7*NR>@% D2*M>S4Q,Q9)H+N6K*Q<GGSRV:\??WOS_-FOKT]>/=\9/?MX
M^O'-Z^>O_^?>X?[ALQ_Y)_CUC_+WZ-F+MZ_^$;WXY>7;-V_?_\</?__U]./K
M'Z(/'__QYO5__##/\O3>>9J=G==/?B_*13+_X7FT,X+OOTSS.BV?/WMU^M_Z
MX<ML6I\_>;3_(,M_B))Y=I;# ])9_0.]YIU^;)&49UE^KRZ63PZ6]=-(?AX7
M=5TL^%>S(J_O5=F_TB>'_N=9LLCFJR<?LT5:1;^GE]'[8I' FT[>G/[R^W_\
M4.(@?WC^[,7SUY_/LW%61S#AZ-F/+YX_^_$=SKAO $<'-SF$":T)C>'P('[$
M_Q=].$]*^/B&D1P>?9V!?/C'[Z]._B=Z]^O)^]].7K[^X^/IRY,W'^+H]/>7
M^YO&])76YN7;WWY[^SN\[^W+_XIVWYV\C_[[Y,T?KZ-_.]@_.#@XC-Z]?A]]
M@/&^WMNX:%]K^_[X_=7K]W]_?_KQ]/=?HI-?WK]^_=OKWS_>R1Z^2B?I8IR6
M_YZ/J^73P_MQ='1P=!S),'Z$\P=#DM,(YXS^]]DRJNK5/ U'ERXZ@\-?+9.S
M]-ZX3)-/]\;IK"C3)\G\,EE5<-*?_;C$E_P*^W'ZOV&NQS_H<TE;//E?C^E_
M?HC^?OKJXZ__\0/LQ]_<!%["BKU^_U?7%^N7]ZOM\O-?BOD4_A%]2";G%;_\
MWY/%\FGTLMB/WKQY22/X>JOP_#_WW^U'OQ7E&8XAG31E5F?P"7@S2M57??7+
MXC+-HR2?PEP7RR1?Q1LF?#,K/OFQB-:M^L[H%I8=+ISH[VE51Q_J,DWKK_TZ
M_.<_BO)3'.F_HL.#HT=']XX.'S_Z^D*.2SXL:%][\L>/CJ/?DFE6%7ET<I'F
M3;INQE]OO0]_>GPKPKWF7'W-.3]X_#AZDW[.\K,Z7.C;ENN#HZ.O+])O0*#@
M-[C*O\"5-D\7:?[D2[:W3C_7][)\"@]Y<O]O5QS%AU4^33Y'[\"T7"23M*FS
M23*OXIW1:3[9CZ,D>I7.DTNP.Z-)42Z+,JDSV)O=^CR-_OU_'=[_Z2F:82PD
M:-/@[QX]W8NC95DLBPK>51=15E6PD3C1*IW/\3?X]2J]2,MD'OT!(R\OX3"G
M917ER2*=1ED>/?OC^8?)>3IMYNFS'_]X#C_*?UC7GN)/T7E:IO"T<#3V>69(
MD3&D*S:DBUF4U15,;+& .55U,?D$$U\F9721S&'$:D8NTY*_TGK3SUFY$*/<
MO&@_^@@?DC4!:Z0JOG@QBCI:@!D%GTCP.$;)=)KA^L,'#^.'1_1_ZR83;9K+
MSLA-YL0_NS.E.,IF-&09+0@<"!L.JXY610-B4D5ENH0OP:]!0BYX/(,3"Y?Q
M??C-X+TP5%BD\^0BC:8I?'<!;B0-(_V<EI.L2N,(9CM.X6,S?:5]54R_(0L-
MO[5LRLEY4L&\JV9R;I;.+EMT5B9@8KK9!D,7T4PGN%9]DGGD)+.8L2@8,>%%
MA-]U5CO"+<%O97DR@S?!B.9S?,M%.E_!XL[2LN0AP5H'R^=W:Y^7C5[:/[4-
MXBT+J+(++QO#+YNZJF'<H)8C'MI9=H$_I+,9#-!)<#)/4?Q@Y1;+>8+KA],9
MKSHS6S>9ESS8#SC88$HMP8/'T7/SPAZ*8*?F6563+MD9J2:)3J,"O\L'BB07
MGXIR%;6D$$?65#()V'06Q$6JWX,_AW*F.XL/J[I/@[\&HS//2S,9$RPBK&LS
MAQTJRF@Y;_#@R K1PGZN8?'^V63PZ/TONJ"N=558M0:'*)IE<UB?2Q@]C="8
M9#C;UY_AI.5G])4%*+W>:T/^8-5T E,\@ZV3FP9$K\:;L<9S_G,!&_7LY[?@
M0,.FBN]W#@MZKUK"Y?4D+R[+9 F7VKWCDP_OG_V(GWP>[?X, Y6OK?G2[\4^
MG^#CX^-[1P_N/WQXN!?K,^ +H"_&Z03N)Q%\V->H6<*H8!WP.,"_?DM O8@:
M8/_OD-8BRR?S9HH+@U=!M81O-Z@QX9C@-]T=X!:P H,>'&A865P"5%57F[H;
M-[^97H);Y)40GP/S2C[L=#M-HUE9+*(:!(#&AO^%<VQ4 RNV@8T"T8!5 B&;
M1DG-9P*?D,%?&I#$A$P,4&KK5C,.1[XSRO(91@W9^J#;:+7W/73QQ<;GSFB:
MI@O6P;#M<"G4JOV'=M5L)7S2[5J>5A7>JU63Y'09O$=%>__XX$74H,)KZX:3
M";WI\/'Q<6Q%)=0-X1="4Z3:&6U[G;RW<_F@<_&/>TH?-V<2-#W^!F4-)+$$
M]YHN 7@T*. 97N1\S\$,Y##M@JKN?FN13.&"NDBR>3*>I[V61'BB\",+].-1
MP8-;3Z]0<Z6$*7>6^/"GX\$5WH-5VOK.?>>F[Q<FN,[\1^%2FV=@@R7ERJR:
M^1I>:*A@\,_^H[0P(E[^;?O1:6AO^$LE@4L[&<-YO,C(DAB029@,_P5F:,P
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MMQ#MD8DOQE&0\39J^/!^ ,*[=5-W,FCJGL"R#D37:):<_=5]R:H@HH*FYE
M:3A+I@FRV%FPXS1>$\[!XSW!( P>*O\)&8C(]>QF#0DYYC2'??8%UJU2/VJ
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M(A>^_2]9&)ARN#*,>;PP+ U^/88&JZ6-U.V)WDUMX4DX)<9<VXTGL;E(Y@[
M[AKAB%&4J3G5UUA^FLV$X Q,BK>U;RMZA1L1=2BE++>Y#GLS?]$E.&H<L-.7
M=;I4K]6I_@2' 3_?PL'3!F[]J,CUKC4P;68<=%CN@-S>>^^=+\37FA2H/F6%
MO.,NVB$=K4Z$^M/9LN(3_ 7; '"LG/'&343@AU?>2PK]"4L;"A<+D?489499
M2[B,*,Z%Z;J4M:*+YZV1*+[&N*[9)"JVW@30Y9ZBU;<44('@N.1 -*?]\3YI
M4%5 ]B%J"<D.5%0ULP!#!TP8,;=P2/TM[-I :T*;E;!!'9Y 7:I8@4[4NK R
MJL[@.;TGZQ#@2; 393%/MSR[U> 2?\/QJ\/O\:L;-<.39.OFW"DZX0Q)#%)Q
ME=CC/B7.C!<D@I)1D^3;L"%>;6F)W]^=[-D:TLW?>C -O^7-ZL"$?]IWI-H3
MB];/*\&I&\5DXR1I7C4*8$+U&A2\(GVD.:A;30SCWNXK;G8M-FN/,^H N^2:
M0Y6@'*LUL5]S$JD94X5__VKAK:<F5DPH=,K538T&G1H5*A:6O).2Q-H]5&PZ
M;_WT>[O]PU C1):4 @VMNQGLOV;1>'(]7X/5P7_KIAO%S,Q9MN4AO*>XI"G,
M5PBDF@AMGO> W Y8B(B:T)_8N@C[,+G+^3Q+9S!!=> 8TL31%OZ;9V[1O[7N
M]9[F*L&^M6U3!;VB$-Q%%'0\7JM^T#M!HWR"UZ<49J_N::TK*R%L(N)^18GM
MJY!T#W63N3*0&6V2,;4$X  E+#\5_G$(C"+V50^RT6@+88\P,+@Q.-+IA>2$
MV:L6)F,4ZU**2J32DZ9.6"0?@=#WTB#<RU>LJ&2$#A8F-/0J0G'+8*Q\L@#_
MH$05PO:D9ZFI?%.'J4NP<@B0!W,78C:9K!4SSTF^'81&3K0%VKEJ8%9%-0TA
MR_MR]N"^^HRLM<Y0GWY*TZ4&2+Q?8B-)MBT<PR#4ZD_R3]A*"1ZT$NWHHHDH
M^A^IR<[IZ:E^ <&0^JX/-9R*,_@M12M/%BGV\<1OO:,8"/W2:,*/!5Z"[\UE
M0P04C!&&Q[T=([<GZ)B/!!G*J@6.B+S7HX.#PVCWCP\GT;N3C^]/WWZDZU>D
MC9!)DO[_61"2'VUDY;U;$Q<W_6D@;FJ)V?(ZN[<H\A1)HD@UDK>G0 EX3!_0
M=J,@:*VXIZ 9O,$H!FO#YWSX66L9-CGZ<AS<?0B]<*VED9<8BR(\$1JQPU$M
M+Y4F<15WP)V(%@53([;P;$%8^ 37Z#=:HS=^C=X0U:2AYN%"Z* "S'%I< T8
MD[?Y+G.&UK%G3+$'C]#7E-H1U]S#3WS;@E96;"CWT=?W<WB&')SJ5+6.L7OO
M-ET![T*G3:=73A3U==()\H.]#337)!IW1JU,H_JO,>TNJB#-.'*&S5?77&R3
MXS0]7Z70P%>M=_!K%HHI3/_*!#!04Y$(UD4_;JJ..>S.7;RTVBC)7<AUS=FK
MM4#@%89<:Z5P_H@W?5,Z*_.M0_JKGCOAL.-+'F)L@>^_BRKXH(BHEPC"R>1#
M(4(HCGZ%&?^6_ G"Z]ZF;_>U8J![T@N,*+AIF8/8SA^YE?Z@'PYT LJ6JV_&
M]CL2N"-"6EXAV'?"SS%3*<5D2T% E&5&(#+MSM!:>O=*@Y"('<2/(OL"L"1A
M*N&@)!2%,]C,K9PIKYS$F7)N+'4$PA54D?W?R1+#S^?_.L\8??9?YRQ(_%[Z
MW!^?2K26XNT&4!7W)E@7/E5'[A7HJ;KZ!!):+.<.Y0W7'Y$V?>E3WS3@"ZQY
MZLMFG"";%%RY<?0[M9OZ+Q!/GN2'%5S^>R'D3=G'XV\WI'3T/:1TO1JX(<1(
M4Z6*R60X@)P>!1V0=IZG2+1-!RT;2U\4#^$ACSFY2, VHGIIZ17'CY/<BN5H
M_K/(0,=@%4E3IMK&PBL]5O=/" 6BK1T,'$0A+A>.FM-"ZPO#2/O.4:A(#=6@
M1HLCX4*HQ9?DQHV-&AL>CL)49</Z[ZEY'4\'UC]/I8"6#J)E@PZ@3UZ)LG6X
M,Y(96("YGQ>5&6+>N+9MDMRV:81;2["9)C7F7 (:"XR,*,I@,T%S_"RP:^2:
M M<';(!5FI3;D/$YMD0T.& 02)2<8Z^!*2&.M#DK=BD;^$3.K1)V1O@Y_HO\
M 0-UB>,L#1*YK0V/-^RXQ/A;.\Y9$7I#ZP7:;"89WO6[,"W3]/\%T]("X/CX
M$,37X-R(\Z'$^?K.K'P,L)!MY;J=+5!58;(]$9IXFYZF7P@YMB^U7&GBQ_<7
M(O^4HZE"[7*6S6I=20R?GD7IG/U]>%:S!JLGFI'--F_7\+IGR5SC\.'A+S2F
M6 95@$EDGV"=N'M]=K58YP77$"FWLR2GA"7:]BI08GW'2Y5,5.LDN1MQ-$G
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MN'V9QN%-JD0CAGN$&X2:OF!S<'#0Z]'B\':]G.,BZ73]6]OITZ6QA31+V$7
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ML90O[XQ,A3&_J=OX3M!%@1XUMXT,<%!8,$>05UCO)=T56ET+)TSH4&,B"RG
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M@^ZBHR\OFHJI(6NJNL8#YO%#*.^1E_;6:7$=7)EF=<70/0SH).4\\P4D"$R
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M%NU9;NT7TZ+5U80'&VL'$4#Q[R*H,MP&3=*Q)J['%RM#:^J;!3E:COTAI/
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M#:? 79]Y-"2*'@0*_/*78CZ%F8,&FIQ7,MUDL7P*U\E^].;-RS@Z.CB(_HX
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M=!3$'UZ*</A;_/.SR,<:,VHW'6,3A:<3D/N\M\*C>XNRO479:J-LU6&V>9>
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M";RX8$,>U]S'V.\:>UW!AG<4X!ZV^$=:7%O0+3;=@.@9JG(B%[9K#'H2Z+,
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MPUTKC$NZ+ 6[M7"Y=VI%,P0O\(,Q$N=A* W$^3\WE)%^LW'0"K0Z"G66^(%
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M>OY@K"@$627(2R$]XW-H0_.0S]1+^<2-/%*_<2@_1;/?NR//_ ]02P,$%
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M[X<UT<VPE6FI_^[,+7!I2!L3^11EP(H6[9<B.45B\,?GKL3)HC/21M'4E!/
M[3B1RA5R.@+>#BI$T=<TM.YN'R;,AA?FGN9PK*]J;=G>-L*.2DN1J4I=5/RZ
MQZ]\!FQJ1#.J,%Z83G&R<^JQDGEEJC:MR>?\2I6!:@=)TL )(" SQ:3":E@2
MD+E&2W)FS5-NC\$8E(+L=IV$@V8+ISB9:BAJ?F5F'1RJF1VN-YQ.CH6U(ZHO
MI1VC#D_3&SSK8=;%'BC*>SA%+7^%U6GGU)ZXOK@.&';8SKW!YJX!0TSCL;3*
MFOI"*OMT;-Y[Q^81T"M>HK,KO(\]%=*.N/ZT=@P[;#]Z@\W=2Z52S:0J<CO
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M>ZFYQ0+[W/+ZB'VS3^%BR=]02P$"% ,4    " "OBX]7V9;<^<P2  !%=
M#0              @ $     9#4P-3 P9#AK+FAT;5!+ 0(4 Q0    ( *^+
MCU? XJEY4YD  *H4 P /              "  ?<2  !D-3 U,#!D97@Q,2YH
M=&U02P$"% ,4    " "OBX]7]/6Q;? )  !Q(@  #P              @ %W
MK   9#4P-3 P9&5X-3$N:'1M4$L! A0#%     @ KXN/5VR)40([ P  1PL
M !$              ( !E+8  '-N9'@M,C R,S$R,30N>'-D4$L! A0#%
M  @ KXN/5S?ZKKB=!@  N4D  !4              ( !_KD  '-N9'@M,C R
M,S$R,31?;&%B+GAM;%!+ 0(4 Q0    ( *^+CU<J'%1<T00  /\M   5
M          "  <[   !S;F1X+3(P,C,Q,C$T7W!R92YX;6Q02P4&      8
,!@!Z 0  TL4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
